

(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 411 678 B2

(12)

NEW EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the opposition decision:
12.01.2000 Bulletin 2000/02

(51) Int Cl.7: C12N 15/16, C12P 21/02,
C12N 5/10, C07K 14/00

(45) Mention of the grant of the patent:
08.01.1992 Bulletin 1992/02

(21) Application number: 90118215.4

(22) Date of filing: 03.12.1985

(54) Method for the production of erythropoietin

Herstellungsverfahren für Erythropoietin
Méthode de production de l'érythropoïétine

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(30) Priority: 04.12.1984 US 677813
03.01.1985 US 688622
22.01.1985 US 693258

(43) Date of publication of application:
06.02.1991 Bulletin 1991/06

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
86900439.0 / 0 205 564

(73) Proprietor: GENETICS INSTITUTE, INC.
Cambridge, Massachusetts 02140 (US)

(72) Inventors:

- Fritsch, Edward
Concord, Massachusetts 01742 (US)
- Jacobs, Kenneth
Newton, Massachusetts 02160 (US)
- Hewick, Rodney M.
Lexington, Massachusetts 02173 (US)

(74) Representative:
 Huber, Bernhard, Dipl.-Chem. et al
 Patentanwälte
 H. Weickmann, Dr. K. Fincke
 F.A. Weickmann, B. Huber
 Dr. H. Liska, Dr. J. Prechtel, Dr. B. Böhm
 Postfach 86 08 20
 81635 München (DE)

(56) References cited:
 EP-A2- 843 086 547 WO-A-85/03079
 GB-A- 2 171 304

- PROC. NATL. ACAD. SCI. USA, vol. 81, May 1984,
pages 2708-2712; S. LEE-HUANG: "Cloning and
expression of human erythropoietin cDNA in
Escherichia coli"
- CHEMICAL ABSTRACTS, vol. 87, 1977, page 294,
abstract no. 129775g, Columbus, Ohio, US; T.
MIYAKE et al.: "Purification of human
erythropoietin", & J. BIOL. CHEM. 1977, 252(15),
5558-64
- NATURE, vol. 313, 28th February 1985, pages
806-810; K. JACOBS et al.: "Isolation and
characterization of genomic and cDNA clones of
human erythropoietin"
- CHEMICAL ABSTRACTS, vol. 105, no. 19, 10th
November 1986, page 203, abstract no. 166280c,
Columbus, Ohio, US; & JP-A-86 12 288
(GENETICS INSTITUTE) 20-01-1986
- EXP. HEMATOL., vol. 12, 1984, page 357,
abstract no. 1; F.K. LIN et al.: "Cloning and
expression of monkey and human
erythropoietin gene"
- Blood, Vol. 62, Nr 5, Suppl. No. 1, Abstract 392,
p. 122a, 1983; Farber et al
- Clin. Res. 31(4), 769A, 1983; Farber
- Molecular and Cellular Biology, Vol. 4, No. 8, PP.
1469-1475, Aug. 1984; Yun-Fai Lau et al
- Journal of Molecular and Applied Genetics, Vol.
2, No. 3, pp. 497-506, 1984; Hsiung et al
- PNAS USA, Vol. 80, 1983, PP. 6838-6842;
Anderson S. and Kingston I.B.
- Nucleic Acids Research, Vol. 11, No. 8, 1983, pp.
2325-2335; Jaye M. et al
- Blood, Vol. 77, 1991, pp. 2624-2632; Wasley et al
- Biotechnology, Vol. 9, 1991, pp. 1347-1355;
Goochée et al
- Endocrinology, Vol. 116, 1985, pp. 2293-2299;
Dordal et al
- Nature, Vol. 313, 1985, pp. 806-810; Jacobs et al

Remarks:

The file contains technical information submitted
after the application was filed and not included in this
specification

Description**FIELD OF THE INVENTION**

5 [0001] The present invention is directed to cloned genes for human erythropoietin that provide surprisingly high expression levels, to the expression of said genes and to the in vitro production of active human erythropoietin.

BACKGROUND OF THE INVENTION

10 [0002] Erythropoietin (hereinafter EPO) is a circulating glycoprotein, which stimulates erythrocyte formation in higher organisms. See, Carnot et al, Compt. Rend., 143 : 384 (1906). As such, EPO is sometimes referred to as an erythropoiesis stimulating factor.

[0003] The life of human erythrocytes is about 120 days. Thus, about 1/120 of the total erythrocytes are destroyed daily in the reticulo-endothelial system. Concurrently, a relatively constant number of erythrocytes are produced daily to maintain the level of erythrocytes at all times (Guyton, Textbook of Medical Physiology, pp 56-60, W.B. Saunders Co., Philadelphia (1976)).

[0004] Erythrocytes are produced by the maturation and differentiation of the erythroblasts in bone marrow, and EPO is a factor which acts on less differentiated cells and induces their differentiation to erythrocytes (Guyton, supra).

[0005] EPO is a promising therapeutic agent for the clinical treatment of anemia or, in particular, renal anemia. Unfortunately, the use of EPO is not yet common in practical therapy due to its low availability.

[0006] For EPO to be used as a therapeutic agent, consideration should be given to possible antigenicity problems, and it is therefore preferable that EPO be prepared from a raw material of human origin. For example, human blood or urine from patients suffering from aplastic anemia or like diseases who excrete large amounts of EPO may be employed. These raw materials however, are in limited supply. See, for example, White et al., Rec. Progr. Horm. Res., 16 : 219 (1960) ; Espada et al., Biochem. Med., 3 : 475 (1970) ; Fisher, Pharmacol. Rev., 24 : 459 (1972) and Gordon, Vitam. Horm. (N.Y.) 31 : 105 (1973), the disclosures of which are incorporated herein by reference.

[0007] The preparation of EPO products has generally been via the concentration and purification of urine from patients exhibiting high EPO levels, such as those suffering from aplastic anemia and like diseases. See for example, U.S. Patent Nos. 4,397,840 ; 4,303,650 and 3,865,801 the disclosures of which are incorporated herein by reference. The limited supply of such urine is an obstacle to the practical use of EPO, and thus it is highly desirable to prepare EPO products from the urine of healthy humans. A problem in the use of urine from healthy humans is the low content of EPO therein in comparison with that from anemic patients. In addition, the urine of healthy individuals contains certain inhibiting factors which act against erythropoiesis in sufficiently high concentration so that a satisfactory therapeutic effect would be obtained from EPO derived therefrom only following significant purification.

[0008] EPO can also be recovered from sheep blood plasma, and the separation of EPO from such blood plasma has provided satisfactorily potent and stable water-soluble preparations. See, Goldwasser, Control Cellular Dif. Develop., Part A ; pp 487-494, Alan R. Liss, Inc., N.Y. (1981), which is incorporated herein by reference. Sheep EPO would however, be expected to be antigenic in humans.

[0009] Thus, while EPO is a desirable therapeutic agent, conventional isolation and purification techniques, used with natural supply sources, are inadequate for the mass production of this compound.

[0010] Sugimoto et al., in U.S. Patent No. 4,377,513 describe one method for the mass production of EPO comprising the in vivo multiplication of human lymphoblastoid cells, including Namalwa, BALL-1, NALL-1 TALL-1 and JBL.

[0011] The reported production by others of EPO using genetic engineering techniques had appeared in the trade literature. However, neither an enabling disclosure nor the chemical nature of the product has yet been published. In contrast, the present application provides an enabling disclosure for the mass production of proteins displaying the biological properties of proteins displaying the biological properties of human EPO. It is also possible by such techniques to produce proteins which may chemically differ from authentic human EPO, yet manifest similar (and in some cases improved) properties. For convenience all such proteins displaying the biological properties of human EPO may be referred to hereinafter as EPO whether or not chemically identical thereto.

50

SUMMARY OF THE INVENTION

[0012] The present invention is directed to the method for producing recombinant human erythropoietin (hEPO) by the steps of

55

- (a) culturing, in a suitable medium, CHO cells which contain, operatively linked to an expression control sequence, a DNA sequence encoding hEPO, and
- (b) recovering and separating the recombinant hEPO produced from the cells and the medium,

characterized in that CHO cells are used which have the capability of producing N- and O-linked glycosylation, with incorporation of fucose and N-acetylgalactosamine, and that recombinant hEPO with N- and O-linked glycosylation is recovered and separated from the cells and the medium, an expression vector containing a gene that expresses surprisingly high levels of human, EPO, the expression thereof, and the mass production *in vitro* of active human EPO therefrom and, expression cells.

[0013] As described in greater detail *infra*, EPO was obtained in partially purified form and was further purified to homogeneity and digested with trypsin to generate specific fragments. These fragments were purified and sequenced. EPO oligonucleotides were designed based on these sequences and synthesized. These oligos were used to screen a human genomic library from which was isolated an EPO gene.

[0014] The EPO gene was verified on the basis of its DNA sequence which matched many of the tryptic protein fragments sequenced. A piece of the genomic clone was then used to demonstrate by hybridization that EPO mRNA could be detected in human fetal (20. week old) mRNA. A human fetal liver cDNA library was prepared and screened. Three EPO cDNA clones were obtained (after screening > 750,000 recombinants). Two of these clones were determined to be full length as judged by complete coding sequence and substantial 5-prime and 3-prime untranslated sequence. These cDNAs have been expressed in both SV-40 virus transformed monkey cells (the COS-1 cell line ; Gluzman, *Cell* 23 : 175-182 (1981)) and Chinese hamster ovary cells (the CHO cell line ; Urlaub, G. and Chasin.L. A *Proc Natl. Acad. Sci USA* 77 : 4216-4280 (1980)). The EPO produced from COS cells is biologically active EPO *in vitro* and *in vivo*. The EPO produced from CHO cells is also biologically active *in vitro* and *in vivo*.

[0015] The EPO cDNA clone has an interesting open reading frame of 14-15 amino acids (aa) with initiator and terminator from 20 to 30 nucleotides (nt) upstream of the coding region. A representative sample of *E. coli* transfected with the cloned EPO gene has been deposited with the American Type Culture Collection, Rockville, Maryland, where it is available under Accession Number ATCC 40153.

BRIEF DESCRIPTION OF DRAWINGS AND TABLES

[0016]

Table 1 is the base sequence of an 87 base pair exon of a human EPO gene ;
 Figure 1 illustrates the detection of EPO mRNA in human fetal liver mRNA ;
 Table 2 illustrates the amino acid sequence of an EPO protein deduced from the nucleotide sequence of lambda-HEPOFL13. ;
 Table 3 illustrates the nucleotide sequence of the EPO cDNA in lambda-HEPOFL13 (shown schematically in Figure 2) and the amino acid sequence deduced therefrom ;
 Figure 3 illustrates the relative positions of DNA inserts of four independent human EPO genomic clones ;
 Figure 4 illustrates a map of the apparent intron and exon structure of the human EPO gene ;
 Table 4 illustrates a DNA sequence of the EPO gene illustrated in Figure 4B ;
 Figures 5A, 5B and 5C illustrate the construction of the vector 91023(B) ;
 Figure 6 illustrates SDS polyacrylamide gel analysis of EPO produced in COS-1 cells compared with native EPO ;
 Table 5 illustrates the nucleotide and amino acid sequence of the EPO clone, lambda-HEPOFL6 ;
 Table 6 illustrates the nucleotide and amino acid sequence of the EPO clone, lambda-HEPOFL8 ;
 Table 7 illustrates the nucleotide and amino acid sequence of the EPO clone lambda-HEPOFL13 ;
 Figure 7 is a schematic illustration of the plasmid pRk1-4 ; and
 Figure 8 is a schematic illustration of the plasmid pdBPV-MMTneo (342-12).

DETAILED DESCRIPTION

[0017] The patent and scientific literature is replete with processes reportedly useful for the production of recombinant products. Generally, these techniques involve the isolation or synthesis of a desired gene sequence, and the expression of that sequence in either a prokaryotic or eucaryotic cell, using techniques commonly available to the skilled artisan. Once a given gene has been isolated, purified and inserted into a transfer vector (i.e., cloned), its availability in substantial quantity is assured. The vector with its cloned gene is transferred to a suitable micro-organism or cell line, for example, bacteria, yeast, mammalian cells such as, COS-1 (monkey kidney), CHO (Chinese hamster ovary), insect cell lines, and the like, wherein the vector replicates as the microorganism or cell line proliferates and from which the vector can be isolated by conventional means. Thus, there is provided a continuously renewable source of the gene for further manipulations, modifications and transfers to other vectors or other loci within the same vector.

[0018] Expression may often be obtained by transferring the cloned gene, in proper orientation and reading frame into an appropriate site in a transfer vector such that translational read-through from a prokaryotic or eucaryotic gene results in synthesis of a protein precursor comprising the amino acid sequence coded by the cloned gene linked to Met

or an amino-terminal sequence from the prokaryotic or eucaryotic gene. In other cases, the signals for transcription and translation initiation can be supplied by a suitable genomic fragment of the cloned gene. A variety of specific protein cleavage techniques may be used to cleave the protein precursor, if produced, at a desired point so as to release the desired amino acid sequence, which may then be purified by conventional means. In some cases, the protein containing the desired amino acid sequence is produced without the need for specific cleavage techniques and may also be released from the cells into the extracellular growth medium.

Isolation of a Genomic Clone of Human EPO

10 [0019] Human EPO was purified to homogeneity from the urine of patients afflicted with aplastic anemia as described infra. Complete digestion of this purified EPO with the protease trypsin, yielded fragments which were separated by reverse phase high performance liquid chromatography, recovered from gradient fractions, and subjected to micro-sequence analysis. The sequences of the tryptic fragments are underlined in Tables 2 and 3 and are discussed in more detail infra. Two of the amino acid sequences, Val-Asn-Phe-TyrAla-Trp-Lys and Val-Tyr-Ser-Asn-Phe-Leu-Arg, were chosen for the design of oligonucleotide probes (resulting in an oligonucleotide pool 17 nt long and 32-fold degenerate, and an oligonucleotide pool 18 nt long and 128-fold degenerate, from the former tryptic fragment, as well as two pools 14 nt long, each 48-fold degenerate, from the latter tryptic fragment, respectively). The 32-fold degenerate 17 mer pool was used to screen a human genomic DNA library in a Ch4A vector (22) using a modification of the Woo and O'Malley *in situ* amplification procedure (47) to prepare the filters for screening.

15 [0020] As used herein, arabic numbers in parentheses, (1) through (61), are used to refer to publications that are listed in numerical order at the end of this specification.

20 [0021] Phage hybridizing to the 17 mer were picked, pooled in small groups and probed with the 14 mer and 18 mer pools. Phage hybridizing to the 17 mer, 18 mer and 14 mer pools were plaque purified and fragments were subcloned into M-13 vectors for sequencing by the dideoxy chain termination method of

25

30

35

40

45

50

55

5

10

15

20

25

30

35

40

45

50

55

THE GREAT EASTERN BRITISH ALBUM

TABLE I

5
10
15
20
25
30
35
40
45
50
55

2

5
10
15
20
25
30
35
40
45
50
55

Val	Glu	Val	Trp	Gln	Gly	Leu	Ala	Leu	70	Leu	Ser	Glu	Ala	Val	Leu	Arg	Gly	Gly	Ala	Ala	80
<u>Leu</u>	<u>Val</u>	<u>Asn</u>	<u>Ser</u>	<u>Ser</u>	<u>Gln</u>	<u>Pro</u>	<u>Trp</u>	<u>Glu</u>	<u>Pro</u>	<u>Leu</u>	<u>Gln</u>	<u>Leu</u>	<u>Ile</u>	<u>Ile</u>	<u>Val</u>	<u>Asp</u>	<u>Lys</u>	<u>Ala</u>	<u>Val</u>	<u>Val</u>	<u>Ser</u>
Gly	Ileu	Arg	Ser	Leu	Thr	Thr	Leu	Ileu	Ileu	Arg	Ala	Ileu	Gly	Ala	Gln	Ilys	Glu	Ala	Ile	Ile	Ile
Pro	Pro	Asp	Ala	Ala	Ser	Ala	Ala	Pro	Ileu	Arg	Thr	Ile	Thr	Ala	Asp	Thr	Pro	Pro	Arg	Ile	Ile
Leu	Leu	Val	Arg	Val	Tyr	Ser	Asn	Pho	Ileu	Arg	Gly	Lys	Leu	Ilys	Leu	Tyr	Thr	Gly	Glu	Glu	Ala

TABLE 2 (CONT.)

ג'נ'ז'

TABLE 3 (CONT'D.)

50 Sanger and Coulson, (23) (1977). The sequence of the region hybridizing to the 32-fold degenerate 17 mer in one of the clones is shown in Table 1. This DNA sequence contains within an open reading frame, the nucleotides which could precisely code for the tryptic fragment used to deduce the 17 mer pool of oligonucleotides. Furthermore, analysis of the DNA sequence indicated that the 17 mer hybridizing region was contained within an 87 bp exon, bounded by potential splice acceptor and donor sites.

[0022] Positive confirmation that these two clones (designated herein, lambda-HEPO1 and lambda-HEPO2) are EPO genomic clones has been obtained by sequencing additional exons containing other tryptic fragment coding information.

Isolation of EPO cDNA Clones

[0023] Northern Analysis (56) of human fetal (20 week old) liver mRNA was conducted using a 95 nt single-stranded probe prepared from an M13 clone containing a portion of the 87 bp exon described in Table 1. As illustrated in Figure 1, a strong signal could be detected in fetal liver mRNA. The precise identification of this band as EPO mRNA was achieved by using the same probe to screen a bacteriophage lambda cDNA library of the fetal liver mRNA (25). Several hybridizing clones were obtained at a frequency of approximately 1 positive per 250,000 recombinants screened. The complete nucleotide and deduced amino acid sequences for these clones (lambda-HEPOFL13 and lambda-HEPOFL8) are shown in Tables 5 and 6. The EPO coding information is contained within 594 nt in the 5-prime half of the cDNA, including a very hydrophobic 27 amino acid leader and the 166 amino acid mature protein.

[0024] The identification of the N-terminus of the mature protein was based on the N-terminal sequence of the protein secreted in the urine of persons with aplastic anemia as illustrated herein (Table 1), and as published by Goldwasser (26), Sue and Sylkowski (27), and by Yangawa (21). Whether this N-terminus (Ala-Pro-Pro-Arg---) represents the actual N-terminus found on EPO in circulation or whether some cleavage occurs in the kidney or urine is presently unknown.

[0025] The amino acid sequences which are underlined in Tables 2 and 3 indicate those tryptic fragments or the portion of the N-terminus for which protein sequence information was obtained. The deduced amino acid sequence agrees precisely with the tryptic fragments which have been sequenced, confirming that the isolated gene encodes human EPO.

Structure and Sequence of the Human EPO Gene

[0026] The relative positions of the DNA inserts of four independent human EPO genomic clones are shown in Figure 3. Hybridization analysis of these cloned DNAs with oligonucleotide probes and with various probes prepared from the two classes of EPO cDNA clones positioned the EPO gene within the approximately 3.3 kb region shown by the darkened line in Figure 3. Complete sequence analysis of this region (see Example 4) and comparison with the cDNA clones, resulted in the map of the intron and exon structure of the EPO gene shown in Figure 4. The EPO gene is divided into 5 exons. Part of exon I, all of exons II, III and IV, and part of exon V, contain the protein coding information. The remainder of exons I and V encode the 5-prime and the 3-prime untranslated sequences respectively.

Transient Expression of EPO in COS Cells

[0027] To demonstrate that biologically active EPO could be expressed in an *in vitro* cell culture system, COS cell expression studies were conducted (58). The vector used for the transient studies, p91023(B), is described in Example 5. This vector contains the adenovirus major late promoter, an SV40 polyadenylation sequence, an SV40 origin of replication, SV40 enhancer, and the adenovirus VA gene. The cDNA insert in lambda-HEPOFL13 (see Table 6) was inserted into the p91023(B) vector, downstream of the adenovirus major late promoter. This new vector is identified as pPTFL13.

[0028] Twenty four hours after transfection of this construct into the M6 strain of COS-1 cells (Horowitz et al, *J. Mol. Appl. Genet.* 2:147-149(1983)), the cells were washed, changed to serum free media, and the cells were harvested 48 hrs. later. The level of release of EPO into the culture supernatant was then examined using a quantitative radioimmunoassay for EPO (55). As shown in Table 8, (Example 6) immunologically reactive EPO was expressed. The biological activity of the EPO produced from COS-1 cells was also examined. In a separate experiment, the vector containing EPO cDNA from lambda-HEPOFL13 was transfected into COS-1 cells and media harvested as described *supra*. EPO in the media was then quantified by the either of two *in vitro* biological assays, ³H-thymidine and CFU-E (12, 29), and by either of two *in vivo* assays, hypoxic mouse and starved rat (30,31) (see Table 9, Example 7). These results demonstrate that biologically active EPO is produced in COS-1 cells. By Western blotting, using a polyclonal anti-EPO antibody, the EPO produced by COS cells has a mobility on SDS-polyacrylamide gels which is identical to that of native EPO prepared from human urine (Example 8). Thus, the extent of glycosylation of COS-1 produced EPO may be similar to that of native EPO.

[0029] Different vectors containing other promoters can also be used in COS cells or in other mammalian or eukaryotic cells. Examples of such other promoters useful in the practice of this invention include SV40 early and late promoters, the mouse metallothionein gene promoter, the promoter found in the long terminal repeats of avian or mammalian retroviruses, the baculovirus polyhedron gene promoter and others. Examples of other cell types useful in the practice of this invention include *E. coli*, yeast, mammalian cells such as CHO (Chinese hamster ovary), C127 (monkey epithelium), 3T3 (mouse fibroblast) CV-1 (African green monkey kidney), and the insect cells such as those from *Sphingopora frugiperda* and *Drosophila melanogaster*. These alternate promoters and/or cell types may enable regulation of the timing or level of EPO expression, producing a cell-specific type of EPO, or the growth of large quantities of EPO producing cells under less expensive, more easily controlled conditions.

[0030] An expression system which retains the benefits of mammalian expression but requires less time to produce a high-level expression cell line is composed of an insect cell line and a DNA virus which reproduces in this cell line. The virus is a nuclear polyhedrosis virus. It has a double-stranded circular DNA genome of 128 kb. The nucleocapsid is rod-shaped and found packaged in two forms, the non-occluded form, a membrane budded virus and an occluded form, packaged in a protein crystal in the infected cell nucleus. These viruses can be routinely propagated in *in vitro* insect cell culture and are amendable to all routine animal virological methods. The cell culture media is typically a nutrient salt solution and 10% fetal calf serum.

[0031] *In vitro*, virus growth is initiated when a non-occluded virus (NOV) enters a cell and moves to the nucleus where it replicates. Replication is nuclear. During the initial phase (8-18 hrs. post-infection) of viral application, nucleocapsids are assembled in the nucleus and subsequently bud through the plasma membrane as NOVs, spreading the infection through the cell culture. In addition, some of the nucleocapsids subsequently (18 + hrs. post-infection) remain in the nucleus and are occluded in a protein matrix, known as the polyhedral inclusion body (PIB). This form is not infectious in cell culture. The matrix is composed of a protein known as polyhedrin, MW 33 kd. Each PIB is approximately 1 mm in diameter, and there can be as many as 100 PIBs per nucleus. There is clearly a great deal of polyhedrin produced late in the infection cycle, as much as 25% of total cellular protein.

[0032] Because the PIB plays no role in the *in vitro* replication cycle, the polyhedrin gene can be deleted from the virus chromosome with no effect on *in vitro* viability. In using the virus as an expression vector, we have replaced the polyhedrin gene coding region with the foreign DNA to be expressed, placing it under the control of the polyhedrin promoter. This results in a non-PIB forming virus phenotype.

[0033] This system has been utilized by several researchers the most noted being Pennock et al. and Smith et al. Pennock et al. (Gregory D. Pennock, Charles Shoemaker, and Lois K. Miller, *Molecular and Cell Biology* 3: 84, p. 399-406) have reported on the high level expression of a bacterial protein, β -galactosidase, when placed under the control of the polyhedrin promoter.

[0034] Another nuclear polyhedrosis virus-derived expression vector has been presented by Smith et al. (Gale E. Smith, Max D. Summers and M. J. Fraser, *Molecular and Cell Biology*, May 16, 1983, pp. 2156-2165). They have demonstrated the effectiveness of their vector through the expression of human B-interferon. The synthesized product was found to be glycosylated and secreted from insect cells, as would be expected. In Example 14, modifications to the plasmid containing the *Autographa californica* nuclear polyhedrosis virus (AcNPV) polyhedron gene are described which allow the easy insertion of the EPO gene into the plasmid so that it may be under the transcriptional control of the polyhedrin promoter. The resulting DNA is co-transfected with intact chromosome DNA from wild type AcNPV into insect cells. A genetic recombination event results in the replacement of the AcNPV polyhedrin gene region with the DNA from the plasmid. The resulting recombinant virus can be identified amongst the viral progeny by its possession of the DNA sequences of the EPO gene. This recombinant virus, upon reinfection of insect cells is expected to produce EPO.

[0035] Examples of EPO expression in CHO, C127 and 3T3, and insect cells are given in Examples 10 and 11 (CHO), 13 (C127 and 3T3) and 14 (insect cells).

[0036] Recombinant EPO produced in CHO cells as in Example 11 was purified by conventional column chromatographic methods. The relative amounts of sugars present in the glycoprotein were analyzed by two independent methods [(i) Reinhold, *Methods in Enzymol.* 50 : 244-249 (Methanolysis) and (ii) Takemoto, H. et al., *Anal. Biochem.* 145 : 245 (1985) (pyridyl amination, together with independent sialic acid determination)]. The results obtained by each of these methods were in excellent agreement. Several determinations were thus made, yielding the following average values wherein N-acetylglucosamine is, for comparative purposes, given a value of 1:

Sugar	Relative molar level
N-Acetylglucosamine	1
Hexoses:	
Galactose	0.9
Mannose	0.5
N-Acetylneurameric acid	1
Fucose	0.2
N-Acetylgalactosamine	0.1

[0037] It is noteworthy that significant levels of fucose and N-acetylgalactosamine were reproducibly observed using both independent methods of sugar analysis. The presence of N-acetylgalactosamine indicates the presence of O-linked glycosylation on the protein. The presence of O-linked glycosylation was further indicated by SDS-PAGE analysis of the glycoprotein following digestion of the glycoprotein with various combinations of glycosidic enzymes. In particular,

following enzymatic removal of all N-linked carbohydrate on the glycoproteins using the enzyme peptide endo F N-glycosidase, the molecular weight of the protein was further reduced upon subsequent digestion with neuraminidase, as determined by SDS-PAGE analysis.

5 [0038] In vitro biological activity of the purified recombinant EPO was assayed by the method of G. Krystal, Exp. Hematol. 11 : 649 (1983) (spleen cell proliferation bioassay) with protein determinations calculated based upon amino acid compositional data. Upon multiple determinations, the in vitro specific activity of the purified recombinant EPO was calculated to be greater than 200,000 units/mg protein. The average value was in the range of about 275,000-300,000 units/mg. protein. Moreover, values higher than 300,000 have also been observed. The in vivo (poly-cythemic mouse assay, Kazal and Erslev, Am. Clinical Lab. Sci., Vol. B, p. 91 (1975))in vitro activity ratios observed for the recombinant material was in the range of 0.7-1.3.

10 [0039] It is interesting to compare the glycoprotein characterization presented above with the characterization for a recombinant CHO-produced EPO material previously reported in International Patent Application Publication No. WO 85102610 (published 20 June 1985). The corresponding comparative sugar analysis described on page 65 of that application reported a value of zero for fucose and for N-acetylgalactosamine and a hexoses : N-acetylgalactosamine ratio of 15.09 : 1. The absence of N-acetylgalactosamine indicates the absence of O-linked glycosylation in the previously reported glycoprotein. In contrast to that material, the recombinant CHO-produced EPO of this invention which is characterized above contains significant and reproducibly observable amounts of both fucose and N-acetylgalactosamine, contains less than one-tenth the relative amount of hexoses and is characterized by the presence of O-linked glycosylation. Furthermore, the high specific activity of the above-described CHO-derived recombinant EPO of this invention may be directly related to its characteristic glycosylation pattern.

15 [0040] The biologically active EPO produced by the prokaryotic or eucaryotic expression of the cloned EPO genes of the present invention can be used for the in vivo treatment of mammalian species by physicians and/or veterinarians. The amount of active ingredient will, of course, depend upon the severity of the condition being treated, the route of administration chosen, and the specific activity of the active EPO, and ultimately will be decided by the attending physician or veterinarian. Such amount of active EPO was determined by the attending physician is also referred to herein as an "EPO treatment effective" amount. For example, in the treatment of induced hypoproliferative anemia associated with chronic renal failure in sheep, an effective daily amount of EPO was found to be 10 units/kg for from 15 to 40 days. See Eschbach et al., J. Clin. Invest., 74 : 434 (1984).

20 [0041] The active EPO may be administered by any route appropriate to the condition being treated. Preferably, the EPO is injected into the bloodstream of the mammal being treated. It will be readily appreciated by those skilled in the art that the preferred route will vary with the condition being treated.

25 [0042] While it is possible for the active EPO to be administered as the pure or substantially pure compound, it is preferable to present it as a pharmaceutical formulation or preparation.

30 [0043] The formulations of the present invention, both for veterinary and for human use, comprise an active EPO protein, as above described, together with one or more pharmaceutically acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

35 [0044] Desirably the formulation should not include oxidizing agents and other substances with which peptides are known to be incompatible. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active Ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.

40 [0045] Formulations suitable for parenteral administration conveniently comprise sterile aqueous solutions of the active ingredient with solutions which are preferably isotonic with the blood of the recipient. Such formulations may be conveniently prepared by dissolving solid active ingredient in water to produce an aqueous solution, and rendering said solution sterile may be presented in unit or multi-dose containers, for example sealed ampoules or vials.

45 [0046] EPO/cDNA as used herein includes the mature EPO/cDNA gene preceded by an ATG codon and EPO/cDNA coding for allelic variations of EPO protein. One allele is illustrated in Tables 2 and 3. The EPO protein includes the 1-methionine derivative of EPO protein (Met-EPO) and allelic variations of EPO protein. The mature EPO protein illustrated by the sequence in Table 2 begins with the sequence Ada.Pro.Pro.Arg... the beginning of which is depicted by the number "1" in Table 2. The Met-EPO would begin with the sequence Met.Ala.Pro.Pro.Arg...

50 [0047] The following examples are provided to aid in the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth, without departing from the spirit of the invention. All temperatures are expressed in degrees Celsius and are uncorrected. The symbol for micron or micro, e.g., microliter, micromole, etc., is "u", e.g., ul, um, etc.

EXAMPLES

Example I : Isolation of a Genomic Clone of EPO

5 [0048] EPO was purified from the urine of patients with aplastic anemia essentially as described previously (Miyake, et al., J. Biol. Chem., **252**; 5558 (1977)) except that the phenol treatment was eliminated and replaced by heat treatment at 80 deg. for 5 min. to inactivate neuraminidase. The final step in the purification was fractionation on a C-4 Vydac HPLC column (The Separations Group) using 0 to 95% acetonitrile gradient with 0.1% trifluoracetic acid (TFA) over 100 minutes. The position of EPO in the gradient was determined by gel electrophoresis and N-terminal sequence analysis (21, 26, 27) of the major peaks. The EPO was eluted at approximately 53% acetonitrile and represented approximately 40% of the protein subjected to reverse phase - HPLC. Fractions containing EPO were evaporated to 100 μ l, adjusted to pH 7.0 with ammonium bicarbonate digested to completion with 2% TPCK-treated trypsin (Worthington) for 18 hrs. at 37 deg. The tryptic digestion was then subjected to reverse phase HPLC as described above. The optical density at both 280 and 214 nm was monitored. Well separated peaks were evaporated to near dryness, and subjected directly to N-terminal amino acid sequence analysis (59) using an Applied Biosystems Model 480 A gas phase sequenator. The sequences obtained are underlined in Tables 2 and 3. As described herein supra, two of these tryptic fragments were chosen for synthesis of oligonucleotide probes. From the sequence, Val-Asn-Phe-Tyr-Ala-Trp-Lys (amino acids 46 through 52 in Tables 2 and 3), a 17 mer of 32 fold degeneracy

20

TTCCANGCGTAGAAGTT

and an 18 mer of 128 fold degeneracy

25

CCANGCGTAGAAGTTNAC

were prepared. From the sequence, Val-Tyr-Ser-Asn-Phe-Leu-Arg (amino acids 144 through 150 in Tables 2 and 3), two pools of 14 mers, each 32-fold degenerate

30

TACACCTAACTTCCT and TACACCTAACTTCTT

35 which differ at the first position of the leucine codon were prepared. The oligonucleotides were labelled at the 5-prime end with 32 P using polynucleotide kinase (New England Biolabs) and gamma 32 P-ATP (New England Nuclear). The specific activity of the oligonucleotides varied between 1000 and 3000 Ci/mmol oligonucleotide. A human genomic DNA library in bacteriophage lambda (Lawn et al., 22) was screened using a modification of the in situ amplification procedure originally described by Woo et al., (47) (1978). Approximately 3.5×10^6 phages were plated at a density of 6000 phage per 150 mm petri dish (NZCYM media) and incubated at 37 deg. until the plaques were visible, but small (approximately 0.5 mm). After chilling at 4 deg. for 1 hr., duplicate replicas of the plaque patterns were transferred to nylon membranes (New England Nuclear) and incubated overnight at 37 deg. on fresh NZCYM plates. The filters were then denatured and neutralized by floating for a 10 min. each on a thin film of 0.5 N NaOH - 1 M NaCl and 0.5 M Tris (pH 8) - 1 M NaCl respectively. Following vacuum baking at 80 deg. for 2 hrs., the filters were washed in 5 \times SSC, 0.5% SDS for 1 hr. and the cellular debris on the filter surface was removed by gentle scrapping with a wet tissue. 40 This scrapping reduced the background binding of the probe to the filters. The filters were then rinsed with H₂O and prehybridized for from 4 to 8 hrs. at 48 deg. in 3 M tetramethylammonium chloride, 10 mM NaPO₄ (pH 6.8), 5 \times Denhardt's, 0.5% SDS and 10 mM EDTA. The 32 P-labeled 17 mer was then added at a concentration of 0.1 pmol/ml and hybridization was carried out at 48 deg. for 72 hrs. Following hybridization the filters were washed extensively in 2 \times SSC (0.3M NaCl - 0.03M Na citrate, pH 7) at room temperature and then for 1 hr. in 3 M TMACl - 10 mM NaPO₄ (pH 6.8) at room temperature and from 5 to 15 min. at the hybridization temperature. Approximately 120 strong duplicate signals were detected following 2 day autoradiography with an intensifying screen. The positives were picked, grouped in pools of 8, replated and rescreened in triplicate using one-half of the 14 mer pool on each of two filters and the 127 mer on the third filter. The conditions and the 17 mer for plating and hybridization were as described supra except that hybridization for the 14 mer was at 37 deg. Following autoradiography, the probe was removed from the 17 mer filter in 50% formamide for 20 min. at room temperature and the filter was rehybridized at 52 deg. with the 18 mer probe. Two independent phage hybridized to all three probes. DNA from one of these phage (designated herein, lambda HEPO1) was digested to completion with Sau3 A and subcloned into M13 for DNA sequence analysis using the dideoxy chain termination method of Sanger and Coulson, (23) (1977). The nucleotide sequence and deduced amino acid

sequence of the open reading frame coding for the EPO tryptic fragment (underlined region) are described herein. Intron sequences are given in lower case letters ; exon sequences (87 nt) are given in upper case. Sequences which agree with consensus splice acceptor (a) and donor (d) sites are underlined. (See Table 4.)

5 Example 2 : Northern Analysis of Human Fetal Liver mRNA

[0049] 5 ug of human fetal liver mRNA (prepared from a 20 week old fetal liver) and adult liver mRNA were electro

10

15

20

25

30

35

40

45

50

55

TABLE 4

150
 200
 250
 300
 350
 400
 450
 500
 550
 600
 650
 700
 750
 800
 850
 900
 950
 1000
 1050
 1100
 1150
 1200
 1250
 1300
 1350
 1400
 1450
 1500
 1550
 1600
 1650
 1700
 1750
 1800
 1850
 1900
 1950
 2000
 2050
 2100
 2150
 2200
 2250
 2300
 2350
 2400
 2450
 2500
 2550
 2600
 2650
 2700
 2750
 2800
 2850
 2900
 2950
 3000
 3050
 3100
 3150
 3200
 3250
 3300
 3350
 3400
 3450
 3500
 3550
 3600
 3650
 3700
 3750
 3800
 3850
 3900
 3950
 4000
 4050
 4100
 4150
 4200
 4250
 4300
 4350
 4400
 4450
 4500
 4550
 4600
 4650
 4700
 4750
 4800
 4850
 4900
 4950
 5000
 5050
 5100
 5150
 5200
 5250
 5300
 5350
 5400
 5450
 5500
 5550
 5600
 5650
 5700
 5750
 5800
 5850
 5900
 5950
 6000
 6050
 6100
 6150
 6200
 6250
 6300
 6350
 6400
 6450
 6500
 6550
 6600
 6650
 6700
 6750
 6800
 6850
 6900
 6950
 7000
 7050
 7100
 7150
 7200
 7250
 7300
 7350
 7400
 7450
 7500
 7550
 7600
 7650
 7700
 7750
 7800
 7850
 7900
 7950
 8000
 8050
 8100
 8150
 8200
 8250
 8300
 8350
 8400
 8450
 8500
 8550
 8600
 8650
 8700
 8750
 8800
 8850
 8900
 8950
 9000
 9050
 9100
 9150
 9200
 9250
 9300
 9350
 9400
 9450
 9500
 9550
 9600
 9650
 9700
 9750
 9800
 9850
 9900
 9950
 10000
 10050
 10100
 10150
 10200
 10250
 10300
 10350
 10400
 10450
 10500
 10550
 10600
 10650
 10700
 10750
 10800
 10850
 10900
 10950
 11000
 11050
 11100
 11150
 11200
 11250
 11300
 11350
 11400
 11450
 11500
 11550
 11600
 11650
 11700
 11750
 11800
 11850
 11900
 11950
 12000
 12050
 12100
 12150
 12200
 12250
 12300
 12350
 12400
 12450
 12500
 12550
 12600
 12650
 12700
 12750
 12800
 12850
 12900
 12950
 13000
 13050
 13100
 13150
 13200
 13250
 13300
 13350
 13400
 13450
 13500
 13550
 13600
 13650
 13700
 13750
 13800
 13850
 13900
 13950
 14000
 14050
 14100
 14150
 14200
 14250
 14300
 14350
 14400
 14450
 14500
 14550
 14600
 14650
 14700
 14750
 14800
 14850
 14900
 14950
 15000
 15050
 15100
 15150
 15200
 15250
 15300
 15350
 15400
 15450
 15500
 15550
 15600
 15650
 15700
 15750
 15800
 15850
 15900
 15950
 16000
 16050
 16100
 16150
 16200
 16250
 16300
 16350
 16400
 16450
 16500
 16550
 16600
 16650
 16700
 16750
 16800
 16850
 16900
 16950
 17000
 17050
 17100
 17150
 17200
 17250
 17300
 17350
 17400
 17450
 17500
 17550
 17600
 17650
 17700
 17750
 17800
 17850
 17900
 17950
 18000
 18050
 18100
 18150
 18200
 18250
 18300
 18350
 18400
 18450
 18500
 18550
 18600
 18650
 18700
 18750
 18800
 18850
 18900
 18950
 19000
 19050
 19100
 19150
 19200
 19250
 19300
 19350
 19400
 19450
 19500
 19550
 19600
 19650
 19700
 19750
 19800
 19850
 19900
 19950
 20000
 20050
 20100
 20150
 20200
 20250
 20300
 20350
 20400
 20450
 20500
 20550
 20600
 20650
 20700
 20750
 20800
 20850
 20900
 20950
 21000
 21050
 21100
 21150
 21200
 21250
 21300
 21350
 21400
 21450
 21500
 21550
 21600
 21650
 21700
 21750
 21800
 21850
 21900
 21950
 22000
 22050
 22100
 22150
 22200
 22250
 22300
 22350
 22400
 22450
 22500
 22550
 22600
 22650
 22700
 22750
 22800
 22850
 22900
 22950
 23000
 23050
 23100
 23150
 23200
 23250
 23300
 23350
 23400
 23450
 23500
 23550
 23600
 23650
 23700
 23750
 23800
 23850
 23900
 23950
 24000
 24050
 24100
 24150
 24200
 24250
 24300
 24350
 24400
 24450
 24500
 24550
 24600
 24650
 24700
 24750
 24800
 24850
 24900
 24950
 25000
 25050
 25100
 25150
 25200
 25250
 25300
 25350
 25400
 25450
 25500
 25550
 25600
 25650
 25700
 25750
 25800
 25850
 25900
 25950
 26000
 26050
 26100
 26150
 26200
 26250
 26300
 26350
 26400
 26450
 26500
 26550
 26600
 26650
 26700
 26750
 26800
 26850
 26900
 26950
 27000
 27050
 27100
 27150
 27200
 27250
 27300
 27350
 27400
 27450
 27500
 27550
 27600
 27650
 27700
 27750
 27800
 27850
 27900
 27950
 28000
 28050
 28100
 28150
 28200
 28250
 28300
 28350
 28400
 28450
 28500
 28550
 28600
 28650
 28700
 28750
 28800
 28850
 28900
 28950
 29000
 29050
 29100
 29150
 29200
 29250
 29300
 29350
 29400
 29450
 29500
 29550
 29600
 29650
 29700
 29750
 29800
 29850
 29900
 29950
 30000
 30050
 30100
 30150
 30200
 30250
 30300
 30350
 30400
 30450
 30500
 30550
 30600
 30650
 30700
 30750
 30800
 30850
 30900
 30950
 31000
 31050
 31100
 31150
 31200
 31250
 31300
 31350
 31400
 31450
 31500
 31550
 31600
 31650
 31700
 31750
 31800
 31850
 31900
 31950
 32000
 32050
 32100
 32150
 32200
 32250
 32300
 32350
 32400
 32450
 32500
 32550
 32600
 32650
 32700
 32750
 32800
 32850
 32900
 32950
 33000
 33050
 33100
 33150
 33200
 33250
 33300
 33350
 33400
 33450
 33500
 33550
 33600
 33650
 33700
 33750
 33800
 33850
 33900
 33950
 34000
 34050
 34100
 34150
 34200
 34250
 34300
 34350
 34400
 34450
 34500
 34550
 34600
 34650
 34700
 34750
 34800
 34850
 34900
 34950
 35000
 35050
 35100
 35150
 35200
 35250
 35300
 35350
 35400
 35450
 35500
 35550
 35600
 35650
 35700
 35750
 35800
 35850
 35900
 35950
 36000
 36050
 36100
 36150
 36200
 36250
 36300
 36350
 36400
 36450
 36500
 36550
 36600
 36650
 36700
 36750
 36800
 36850
 36900
 36950
 37000
 37050
 37100
 37150
 37200
 37250
 37300
 37350
 37400
 37450
 37500
 37550
 37600
 37650
 37700
 37750
 37800
 37850
 37900
 37950
 38000
 38050
 38100
 38150
 38200
 38250
 38300
 38350
 38400
 38450
 38500
 38550
 38600
 38650
 38700
 38750
 38800
 38850
 38900
 38950
 39000
 39050
 39100
 39150
 39200
 39250
 39300
 39350
 39400
 39450
 39500
 39550
 39600
 39650
 39700
 39750
 39800
 39850
 39900
 39950
 40000
 40050
 40100
 40150
 40200
 40250
 40300
 40350
 40400
 40450
 40500
 40550
 40600
 40650
 40700
 40750
 40800
 40850
 40900
 40950
 41000
 41050
 41100
 41150
 41200
 41250
 41300
 41350
 41400
 41450
 41500
 41550
 41600
 41650
 41700
 41750
 41800
 41850
 41900
 41950
 42000
 42050
 42100
 42150
 42200
 42250
 42300
 42350
 42400
 42450
 42500
 42550
 42600
 42650
 42700
 42750
 42800
 42850
 42900
 42950
 43000
 43050
 43100
 43150
 43200
 43250
 43300
 43350
 43400
 43450
 43500
 43550
 43600
 43650
 43700
 43750
 43800
 43850
 43900
 43950
 44000
 44050
 44100
 44150
 44200
 44250
 44300
 44350
 44400
 44450
 44500
 44550
 44600
 44650
 44700
 44750
 44800
 44850
 44900
 44950
 45000
 45050
 45100
 45150
 45200
 45250
 45300
 45350
 45400
 45450
 45500
 45550
 45600
 45650
 45700
 45750
 45800
 45850
 45900
 45950
 46000
 46050
 46100
 46150
 46200
 46250
 46300
 46350
 46400
 46450
 46500
 46550
 46600
 46650
 46700
 46750
 46800
 46850
 46900
 46950
 47000
 47050
 47100
 47150
 47200
 47250
 47300
 47350
 47400
 47450
 47500
 47550
 47600
 47650
 47700
 47750
 47800
 47850
 47900
 47950
 48000
 48050
 48100
 48150
 48200
 48250
 48300
 48350
 48400
 48450
 48500
 48550
 48600
 48650
 48700
 48750
 48800
 48850
 48900
 48950
 49000
 49050
 49100
 49150
 49200
 49250
 49300
 49350
 49400
 49450
 49500
 49550
 49600
 49650
 49700
 49750
 49800
 49850
 49900
 49950
 50000
 50050
 50100
 50150
 50200
 50250
 50300
 50350
 50400
 50450
 50500
 50550
 50600
 50650
 50700
 50750
 50800
 50850
 50900
 50950
 51000
 51050
 51100
 51150
 51200
 51250
 51300
 51350
 51400
 51450
 51500
 51550
 51600
 51650
 51700
 51750
 51800
 51850
 51900
 51950
 52000
 52050
 52100
 52150
 52200
 52250
 52300
 52350
 52400
 52450
 52500
 52550
 52600
 52650
 52700
 52750
 52800
 52850
 52900
 52950
 53000
 53050
 53100
 53150
 53200
 53250
 53300
 53350
 53400
 53450
 53500
 53550
 53600
 53650
 53700
 53750
 53800
 53850
 53900
 53950
 54000
 54050
 54100
 54150
 54200
 54250
 54300
 54350
 54400
 54450
 54500
 54550
 54600
 54650
 54700
 54750
 54800
 54850
 54900
 54950
 55000
 55050
 55100
 55150
 55200
 55250
 55300
 55350
 55400
 55450
 55500
 55550
 55600
 55650
 55700
 55750
 55800
 55850
 55900
 55950
 56000
 56050
 56100
 56150
 56200
 56250
 56300
 56350
 56400
 56450
 56500
 56550
 56600
 56650
 56700
 56750
 56800
 56850
 56900
 56950
 57000
 57050
 57100
 57150
 57200
 57250
 57300
 57350
 57400
 57450
 57500
 57550
 57600
 57650
 57700
 57750
 57800
 57850
 57900
 57950
 58000
 58050
 58100
 58150
 58200
 58250
 58300
 58350
 58400
 58450
 58500
 58550
 58600
 58650
 58700
 58750
 58800
 58850
 58900
 58950
 59000
 59050
 59100
 59150
 59200
 59250
 59300
 59350
 59400
 59450
 59500
 59550
 59600
 59650
 59700
 59750
 59800
 59850
 59900
 59950
 60000
 60050
 60100
 60150
 60200
 60250
 60300
 60350
 60400
 60450
 60500
 60550
 60600
 60650
 60700
 60750
 60800
 60850
 60900
 60950
 61000
 6105

5
10
15
20
25
30
35
40
45
50
55

TABLE 4 (CONT.)

TABLE 4 (CONT'D.)

40 phoresed in a 0.8% agarose formaldehyde gel and transferred to nitrocellulose using the method of Derman et al.,
Cell, 23 : 731 (1981). A single-stranded probe was then prepared from an M 13 template containing the insert illustrated
in Table 1. The primer was a 20 mer derived from the same tryptic fragment as the original 17 mer probe. The probe
was prepared as previously described by Anderson et al., PNAS, (50) (1984) except that, following digestion with SmaI
45 (which produced the desired probe of 95 nt length containing 74 nt of coding sequence), the small fragment was purified
from the M13 template by chromatography on a sepharose C14B column In 0.1 N NaOH- 0.2 M NaCl. The filter was
hybridized to approximately 5×10^8 cpm of this probe for 12 hrs. at 68 deg., washed in 2 \times SSC at 68 deg. and
exposed for 6 days with an intensifying screen. A single marker mRNA of 1200 nt (indicated by the arrow) was run in
an adjacent lane. (Figure 1).

50 Example 3 : Fetal Liver cDNA

[0050] A probe identical to that described in Example 2 was prepared and used to screen a fetal liver cDNA library prepared in the vector lambda-Ch21A (Toole et al., *Nature*, (25) (1984)) using standard plaque screening (Benton Davis, *Science*, (54) (1978)) procedures. Three independent positive clones (designated herein, lambda-HEPOFL6 (1350 bp), lambda-HEPOFL8 (700 bp) and lambda-HEPOFL13 (1400 bp) were isolated following screening of 1×10^6 plaques. The entire insert of lambda-HEPOFL13 and lambda-HEPOFL6 were sequenced following subcloning into M13. (Tables 7 and 5, respectively). Only portions of lambda-HEPOFL8 were sequenced and the remainder assumed to be identical to the other two clones. (Table 6). The 5-prime and 3-prime untranslated sequences are represented

by lower case letters. The coding region is represented by upper case letters.

TABLE 5
EFFECTS OF VARIOUS
CULTIVARS ON
YIELD AND
QUALITY OF
CABBAGE

5

10

15

20

25

30

35

40

45

50

53

TABLE 5 (CONT'D.)

ככמגנרטור 6

cttcgttcgc	tgcgtcgac	cgcgtgtc	tccgtggcc	ggaccgtggcc	caccggccc	gtctgtccg	acccggccc
ccctgttcgg	ccgttttc	cttcaggccc	gttgggtctgg	ccctgtccgg	ccgggttcc	gttctgtccg	cccccgggtgt
ggtcgtccgg	gtcgctgagg	gaccggcc	aggcggtgg	gggggtttcc	gtttttttcc	gtttttttcc	gtttttttcc
ALA	TRP	LEU	LEU	SER	LEU	PRO	VAL
CCC	TCC	TCC	CTG	TCC	CTG	CTC	CTG
Ala	Pro	Pro	Arg	Lys	Arg	Val	Leu
CCC	CCA	CCC	CTC	TCT	GAC	ACC	CCA
Ala	Asn	Asn	Asn	Asn	Asn	Asn	Asn
CCC	GAG	GAT	ATC	AGC	GGC	TCT	TCT
Val	Pro	Asp	Thr	Lys	Val	Asn	Asn
CTG	CCA	GAC	ACC	AAA	GTT	AAT	ATC
Val	Val	Val	Val	Val	Val	Val	Val
GAA	CAA	GTC	TCC	GCC	GTC	GAA	GTC

5

10

15

20

25

30

35

40

45

50

55

Leu	Val	Ala	Ser	Ser	Ser	Pro	Trp	Glu	Pro	Leu	Gln	Leu	Ile	Val	Asp	Lys	Ala	V _u l	
TTC	GTC	AAC	TCT	TCC	CAG	CCC	TCC	CAC	CCC	CTG	CAC	CTG	CAT	CTG	CAT	AAA	GCC	GTC	Ser
Gly	Ile	Arg	Ser	Leu	Thr	Thr	Leu	Leu	Arg	Ala	Leu	Gly	Ala	Gln	Lys	Glu	Ala	Ile	
CCC	CTT	GGC	ACC	CTC	ACC	ACT	CTG	CTT	GGC	GCT	CTG	GCA	GCC	CAG	AAG	GAA	GCC	ATC	TCC
Pro	Pro	Asp	Ala	Ala	Ser	Ala	Ala	Pro	Leu	Arg	Thr	Ile	Thr	Ala	Asp	Thr	Phe	Arg	
CCT	CCA	CAT	GGG	CCC	TCA	GCT	GCT	CCA	CTC	CGA	ACA	ATC	ACT	CCT	GAC	ACT	TTC	CGC	LYe AAA
Leu	Phe	Arg	Val	Tyr	Ser	Asn	Phe	Leu	Arg	Gly	Lys	Leu	Lys	Leu	Tyr	Thr	Gly	Glu	
CTC	TTC	CCA	GTC	TAC	TCC	AAT	TTC	CTC	GGG	GCA	AAC	CTG	AAC	CTG	TAC	ACA	GGC	GAC	

TABLE 6 (CONT.)

ccccccgg		ccggccatc		ccccggcc		ccggatcc		ccccccgg		ccggatcc		ccccccgg	
Ala	Pro	Pro	Arg	Leu	Ile	Cys	Asp	Ser	Arg	Val	Ile	Cys	Pro
CCG	CCC	CCC	CCC	CTC	ATC	CTC	ATC	CTC	CCC	CTC	CTC	CTC	CCT
Ala	Pro	Pro	Arg	Leu	Ile	Cys	Asp	Ser	Arg	Val	Ile	Cys	Pro
CCG	CCC	CCC	CCC	CTC	ATC	CTC	ATC	CTC	CCC	CTC	CTC	CTC	CCT
Ala	Ala	Ala	Asn	Ile	Thr	Cys	Ala	Glu	Asp	Tyr	Leu	Cys	Ala
CCG	CCC	CCC	CCC	ATC	ATC	CCC	CTC	CTC	ACC	TTC	CTC	TAG	CCG
Ala	Ala	Ala	Asn	Ile	Thr	Cys	Ala	Glu	Asp	Tyr	Leu	Cys	Ala
CCG	CCC	CCC	CCC	ATC	ATC	CCC	CTC	CTC	ACC	TTC	CTC	TAG	CCG
Val	Pro	Asp	Thr	Lys	Val	Ala	Trp	Lys	Arg	Val	Gly	Cys	Ala
GTC	CCA	GAC	ACC	AAA	CTT	ATC	TAT	CCC	TCA	ACC	ATC	GAC	CCC
Val	Val	Val	Val	Gly	Ileu	Ala	Ileu	Ser	Glu	Ala	Val	Gly	Ala
GTA	CAA	GTC	TCG	CCC	CTC	CCC	CTC	CTG	TCA	CCT	CTG	CTG	CCC
Ileu	Val	Asn	Ser	Ser	Gly	Ileu	Ileu	Leu	Glu	Leu	Arg	Gly	Ileu
ITC	GTC	AAC	TCT	TCC	CAG	CCC	TCA	GAC	CCC	CTG	CAT	AAA	CCC
Ileu	Val	Asn	Ser	Ser	Gly	Ileu	Ileu	Leu	Glu	Leu	Arg	Gly	Ileu
ITC	GTC	AAC	TCT	TCC	CAG	CCC	TCA	GAC	CCC	CTG	CAT	AAA	CCC
Ala	Leu	Leu	Thr	Leu	Leu	Gly	Ala	Leu	Gly	Leu	Asp	Ileu	Val
CCG	CTT	CTC	ATC	ATC	CTT	CCC	CTC	CTG	CTG	CTG	CTG	CTG	CTC
Ala	Leu	Leu	Thr	Leu	Leu	Gly	Ala	Leu	Gly	Leu	Asp	Ileu	Val
CCG	CTT	CTC	ATC	ATC	CTT	CCC	CTC	CTG	CTG	CTG	CTG	CTG	CTC

TABLE 7 (CONT'D.)

50 [0051] With reference to Tables 2 and 3, the deduced amino acid sequence shown below the nucleotide sequence is numbered beginning with 1 for the first amino acid of the mature protein. The putative leader peptide is indicated by all caps for the amino acid designations. Cysteine residues in the mature protein are additionally indicated by SH and potential N-linked glycosylation sites by an asterisk. The amino acids which are underlined indicate those residues identified by N-terminal protein sequencing or by sequencing tryptic fragments of EPO as described in Example 1.
55 Partial underlining indicates residues in the amino acid sequence of certain tryptic fragments which could not be determined unambiguously. The cDNA clones lambda-HEPOFL6, lambda-HE-POFL8 and lambda-HEPOFL13 have been deposited and are available from the American Type Culture Collection, Rockville, Maryland as Accession Numbers ATCC 40156, ATCC 40152 and ATCC 40153, respectively.

Example 4 : Genomic Structure of the EPO Gene

[0052] The relative sizes and positions of four independent genomic clones (lambda-HEPO1, 2, 3, and 6) from the HaeIII/AluI library are illustrated by the overlapping lines in Figure 3. The thickened line indicates the position of the EPO gene. A scale (in Kb) and the positions of known restriction endonuclease cleavage sites are shown. The region containing the EPO gene was completely sequenced from both strands using directed exonuclease III generated series of deletions through this region. A schematic representation of five exons coding for EPO mRNAs is shown in Figure 4. The precise 5-prime boundary of exon 1 is presently unknown. The protein coding portion of the exons are darkened. The complete nucleotide sequence of the region is shown in Table 4. The known limits of each exon are delineated by the solid vertical bars. Genomic clones lambda-HEPO1, lambda-HEPO2, lambda-HEPO3 and lambda-HEPO6 have been deposited and are available from the American Type Culture Collection, Rockville, Maryland as Accession Numbers ATCC 40154, ATCC 40155, ATCC 40150, and ATCC 40151, respectively.

Example 5 : Construction of Vector p91023(b)

[0053] The transformation vector was pAdD26SVpA(3) described by Kaufman et al., Mol. Cell Biol., 2: 1304 (1982). The structure of this vector is shown in Fig. 5A. Briefly, this plasmid contains a mouse dihydrofolate reductase (DFHR) cDNA gene that is under transcriptional control of the adenovirus 2 (Ad2) major late promoter. A 5-prime splice site is indicated in the adenovirus DNA and a 3-prime splice site, derived from an immunoglobulin gene, is present between the Ad2 major late promoter and the DFHR coding sequence. The SV40 early polyadenylation site is present downstream from the DFHR coding sequence. The prokaryotic derived section of pAdD26SVpA(3) is from pSVOD (Mellon et al., Cell, 27: 279 (1981)) and does not contain the pBR322 sequences known to inhibit replication in mammalian cells (Lusky et al., Nature, 293 : 79 (1981)).

[0054] pAdD26SVpA(3) was converted to plasmid pCVSVL2 as illustrated in Fig. 5A. pAdD26SVpA(3) was converted to plasmid pAdD26SVpA(3)(d) by the deletion of one of the two PstI sites in pAdD26SVpA(3). This was accomplished by a partial digestion with PstI using a deficiency of enzyme such that a subpopulation of linearized plasmids are obtained in which only one PstI site was cleaved, followed by treatment with Klenow, ligation to recircularize, and screening for deletion of the PstI site located 3-prime to the SV40 polyadenylation sequence.

[0055] The adenovirus tripartite leader and virus associated genes (VA genes) were inserted into pAdD26SVpA(3)(d) as illustrated in Fig. 5A. First, pAdD26SVpA(3)(d) was cleaved with PvuII to make a linear molecule opened within the 3-prime portion of the three elements comprising the tripartite leader. Then, pJAW 43 (Zain et al., Cell, 16 : 851 (1979)) was digested with XbaI, treated with Klenow, digested with PvuII, and the 140 bp fragment containing the second part of the third leader was isolated by electrophoresis on an acrylamide gel (6% in Tris borate buffer; Maniatis et al., supra). The 140 bp fragment was then ligated to the PvuII digested pAdD26SVpA(3)(d). The ligation product was used to transform E. coli to tetracycline resistance and colonies were screened using the Grunstein-Hogness procedure employing a ³²P labelled probe hybridizing to the 140 bp fragment. DNA was prepared from positively hybridizing colonies to test whether the PvuII site reconstructed was 5-prime or 3-prime of the inserted 140 bp DNA specific to the second and third adenovirus late leaders. The correct orientation of the PvuII site is on the 5-prime side of the 140 bp insert. This plasmid is designated tTPL in Fig. 5A.

[0056] The AvaII D fragment of SV40 containing the SV40 enhancer sequence was obtained by digesting SV40 DNA with AvaII, blunting the ends with the Klenow fragment of Pol ligating XbaI linkers to the fragments, digesting with XbaI to open the XbaI site, and isolating the fourth largest (D) fragment by gel electrophoresis. This fragment was then ligated to XbaI cut pTPL, yielding the plasmid pCVSVL2-TPL. The orientation of the SV40 D fragment in pCVSVL2-TPL was such that the SV40 late promoter was in the same orientation as the adenovirus major late promoter.

[0057] To introduce the adenovirus associated (VA) genes into the pCVSVL2-TPL, first a plasmid pBR322 was constructed that contained the adenovirus type 2 HindIII B fragment. Adenovirus type 2 DNA was digested with HindIII and the B fragment was isolated by gel electrophoresis. This fragment was inserted into pBR322 which had previously been digested with HindIII. After transformation of E. coli to ampicillin resistance, recombinants were screened for insertion of the HindIII B fragment and the inserted orientation was determined by restriction enzyme digestion. pBR322 - Ad HindIII B contains the adenovirus type 2 HindIII B fragment in the orientation depicted in Fig. 5B.

[0058] As illustrated in Fig. 5B, the VA genes are conveniently obtained from plasmid pBR322 - Ad HindIII B by digestion with HpaI, adding EcoRI linkers and digestion with EcoRI, followed by recovery of the 1.4 kb fragment. The fragment having EcoRI sticky ends is then ligated into the EcoRI site of PTL, previously digested with EcoRI. After transforming E. coli HB101 and selecting for tetracycline resistance, colonies were screened by filter hybridization to DNA specific for the VA genes. DNA was prepared from positively hybridizing clones and characterized by restriction endonuclease digestion. The resulting plasmid is designated p91023.

[0059] As illustrated in Fig. 5C, the two EcoRI sites in p91023 were removed by cutting p91023 to completion with

EcoRI, generating two DNA fragments, one about 7 kb and the other about 1.3 kb. The latter fragment contained the VA genes. The ends of both fragments were filled in using the Klenow fragment of poll and the two fragments were then ligated together. A plasmid p91023(A), containing the VA genes and similar to p91023, but deleted for the two EcoRI sites, was identified by Grunstein-Hogness screening with the Va gene fragment, and by conventional restriction site analysis.

[0060] The single PstI site in p91023(A) was removed and replaced with an EcoRI site. p91023(a) was cut to completion with PstI and treated with the Klenow fragment of poll to generate flush ends. EcoRI linkers were ligated to the blunted PstI site of p91023(A). The linear p91023(A), with EcoRI linkers attached at the blunted PstI site was separated from unligated linkers and digested to completion with EcoRI, and religated. A plasmid, p91023(B) as depicted in Figure 5C was recovered, and identified as having a structure similar to p91023(A), but with an EcoRI site in place of the former PstI site. Plasmid p91023(B) has been deposited and is available from the American Type Culture Collection, Rockville, Maryland as Accession Number ATCC 39754.

Example 6 :

[0061] The cDNA clones (lambda-EPOFL6 and lambda-EPOFL13; Example 3) were inserted into the plasmid p91023 (B) forming PPTFL6 and PPTFL13, respectively. 8 ug of each of the purified DNA's was then used to transfect 5×10^6 COS cells using the DEAE-dextran method (*infra*). After 12 hrs., the cells were washed and treated with Chloroquin (0.1 mM) for 2 hrs., washed again, and exposed to 10 ml media containing 10% fetal calf serum for 24 hrs. The media was changed to 4 ml serum free media and harvested 48 hrs. later.

[0062] Production of immunologically active EPO was quantified by a radioimmunoassay as described by Sherwood and Goldwasser (55). The antibody was provided by Dr. Judith Sherwood. The iodinated tracer was prepared from the homogeneous EPO described in Example 1. The sensitivity of the assay is approximately 1 ng/ml. The results are shown below in Table 8.

TABLE 8

VECTOR	LEVEL OF EPO RELEASED INTO THE MEDIA (ng/ml)
pPTFL13	330
pPTFL6	31

PTFL13 has been deposited and is available from the American Type Culture Collection, Rockville, Maryland under Accession No. ATCC 39990.

Example 7 :

[0063] EPO cDNA (lambda-HEPOFL13) was inserted into the p91023(B) vector and was transfected into COS-1 cells and harvested as described above (Example 6) except that the chloroquin treatment was omitted.

[0064] *In vitro* biologically active EPO was measured using either a colony forming assay with mouse fetal liver cells as a source of CFU-E or a 3 H-thymidine uptake assay using spleen cells from phenylhydrazine injected mice. The sensitivities of these assays are approximately 25 mUnits/ml. *In vivo* biologically active EPO was measured using either the hypoxic mouse or starved rat method. The sensitivity of these assays is approximately 100 mU/ml. No activity was detected in either assay from mock condition media. The results of EPO expressed by clone EPOFL13 are shown below in Table 9 wherein the activities reported are expressed in units/ml, using a commercial, quantified EPO (Toyobo, Inc.) as a standard.

TABLE 9

EPO Excreted from COS Cells Transfected with Type I EPO cDNA		
Assay	Activity	
RIA	100	ng/ml
cFU-E	2	0.5 U/ml
3 H-Thy	3.1	1.8 U/ml
hypoxic mouse	1	U/ml
starved rat	2	U/ml

Example 8 : SDS Polyacrylamide Gel Analysis of EPO from COS Cells

[0065] 180 ng of EPO released into the media of COS cells transfected with EPO (*lambda*-HEPOFL13) cDNA in the vector 91023(B) (*supra*) was electrophoresed on a 10% SDS Laemmli polyacrylamide gel and electrotransferred to nitrocellulose paper (Towbin et al., Proc. Natl. Acad. Sci. USA 76 : 4350 (1979)). The filter was probed with anti-EPO antibody as described in Table 8, washed, and reprobed with 125 I-staph A protein. The filter was autoradiographed for two days. Native homogeneous EPO was described in Example 1, either before (lane B) or after iodination (lane C) were electrophoresed (see Figure 6). Markers used included 35 S methionine labelled, serum albumin (68,000 d) and ovalbumin (45,000 d).

10

Example 9 : Construction of RK1-4

[0066] The Barn HI-PvuII fragment from the plasmid PSV2DHFR (Subramani et al., Mol. Cell. Biol. 1: 854-864 (1981)) containing the SV40 early region promoter adjacent to the mouse dihydrofolate reductase (DHFR) gene, an SV40 enhancer, the small t antigen intron, and the SV40 polyadenylation sequence was isolated (fragment A). The remaining fragments were obtained from the vector p91023(A) (*supra*) as follows: p91023(A) was digested with Pst I at the single Pst I site near to the adenovirus promoter to linearize the plasmid and either ligated to synthetic Pst I to EcoRI converters and recircularized (creating the sites Pst I - EcoRI - Pst I at the original Pst I site ; 91023(B')) or treated with the large fragment of DNA polymerase I to destroy the Pst I sites and ligated to a synthetic EcoRI linker and recircularized (creating an EcoRI site at the original Pst I site ; 91023(B)). Each of the two resulting plasmids 91023(B) and 91023(B') were digested with Xba and EcoRI to produce two fragments (F and G). By joining fragment F from p91023(B) and fragment G from p91023(B') and fragment G from p91023(B) and fragment F from p91023(B') two new plasmids were created which contained either an EcoRI - Pst I site or a Pst I - EcoRI site at the original Pst I site. The plasmid containing the Pst I - EcoRI site where the Pst I site is closest to the adenovirus major late promoter was termed p91023(C).

25

[0067] The vector p91023(C) was digested with Xhol to completion and the resulting linearized DNA with sticky ends was blunted by an end filling reaction with the large fragment of *E. coli* of DNA polymerase I. To this DNA was ligated a 340 bp Hind III EcoRI fragment containing the SV40 enhancer prepared as follows :

30

[0068] The Hind III - Pvu II fragment from SV40 which contains the SV40 origin of replication and the enhancer was inserted into the plasmid c lac (Little et al., Mol. Biol. Med. 1: 473-488 (1983)). The c lac vector was prepared by digesting c lac DNA with BamHI, filling in the sticky end with the large fragment of DNA polymerase I and digesting the DNA with Hind III. The resulting plasmid (cSVHPIaC) regenerated the BamHI site by ligation to the Pvu II blunt end. The EcoRI - Hind III fragment was prepared from cSVHPIaC and ligated to the EcoRI - Hind III fragment of pSVOd (Mellon et al., *supra*) which contained the plasmid origin of replication and the resulting plasmid PSVHPOd was selected. The 340 bp EcoRI - Hind III fragment of PSVHPOd containing the SV40 origin enhancer was then prepared, blunted at both ends with the large fragment of DNA polymerase I, and ligated to the Xhol digested, blunted p91023 (c) vector described above. The resulting plasmid (p91023(C)/Xho/blunt plus ECORI/Hind III/blunt SV40 origin plus enhancer) in which the orientation of the Hind III - EcoRI fragment was such that the BamHI site within that fragment was nearest to the VA gene was termed pES105. The plasmid pES105 was digested with Bam HI and PvuII and also with PvuII alone and the BamHI - PvuII fragment containing the adenovirus major late promoter (fragment B) and the PvuII fragment containing the plasmid resistance gene (tetracycline resistance) and other sequences (fragment C) were isolated. Fragments A, B and C were ligated and the resulting plasmid shown in Figure 7 was isolated and termed RK1-4. Plasmid RK1-4 has been deposited with the American Type Culture Collection, Rockville, Maryland, where it is available under Accession Number ATCC 39940.

45

Example 10 : Expression of EPO in CHO cells-Method I

50

[0069] DNA (20 ug) from the plasmid pPTFL13 described above (Example 6) was digested with the restriction endonuclease Cla I to linearize the plasmid and was ligated to Cla I-digested DNA from the plasmid pAdD26SVP(A) 1 (2 ug) which contains an intact dihydrofolate reductase (DHFR) gene driven by an adenovirus major late promoter (Kaufman and Sharp, Mol. and Cell Biol. 2 : 1304-1319 (1982)). This ligated DNA was used to transfect DHFR-negative CHO cells (DUKX-BII, Chasin L.A. and Urlaub G. (1980) PNAS 77 4216-4220) and following growth for two days, cells which incorporated at least one DHFR gene were selected in alpha media lacking nucleotides and supplemented with 10% dialyzed fetal bovine serum. Following growth for two weeks in selective media, colonies were removed from the original plates, pooled into groups of 10-100 colonies per pool, replated and grown to confluence in alpha media lacking nucleotides. The supernatant media from the pools grown prior to methotrexate selection were assayed for EPO by RIA. Pools which showed positive EPO production were grown in the presence of methotrexate (0.02 uM) and then subcloned and reassayed. EPO Cla 4 4.02-7, a single subcloned from the EPO Cla 4 4.02 pool, releases 460 ng/ml EPO into media containing 0.02 uM MTX (Table 10). EPO Cla 4 4.02-7 is the cell line of choice for EPO production

and has been deposited with the American Type Culture Collection as Accession Number ATCC CRL8695. Currently, this clone is being subjected to stepwise selection in increasing concentrations of MTX, and will presumably yield cells which produce even higher levels of EPO. For pools which were negative by RIA, methotrexate resistant colonies obtained from the counterpart cultures which were grown in the presence of methotrexate (0.02 uM) were again re-assayed in pools for EPO by RIA. Those cultures which were not positive were subcloned and subjected to growth in further increasing concentrations of methotrexate.

[0070] Stepwise methotrexate (MTX) selection was achieved by repeated cycles of culturing the cells in the presence of increasing concentrations of methotrexate and selecting for survivors. At each round, EPO was measured in the culture supernatant by RIA and by *in vitro* biological activity. The levels of methotrexate used in each stepwise amplification were 0.02 uM, 0.1 uM, and .5 uM. As shown in Table 10 after 1 round of selection in .02 uM MTX significant levels of EPO were being released into the culture media.

TABLE 10

Level of EPO Released into the Media				
	Sample	Assay	Alpha medium harvest	0.02 uM methotrexate in alpha medium harvest
15	4 4	Pool	RIA	17 ng/ml
20	4 4	Single Colony	RIA	50 ng/ml
25		Clone (.02-7)	RIA	460 ng/ml

Example 11 : Expression of EPO in CHO cells - Method II

[0071] DNA from the clone lambda HEPOFL13 was digested with EcoRI and the small RI fragment containing the EPO gene was subcloned into the EcoRI site of the plasmid RK14 (See Example 10). This DNA (RKFL13) was then used to transfet the DHFR-negative CHO cells directly (without digestion) and the selection and amplification was carried out as described in Example 10 above.

[0072] The RKFL13 DNA was also inserted into CHO cells by protoplast fusion and microinjection. Plasmid RKFL13 has been deposited and is available from the American Type Culture Collection, Rockville, Maryland under Accession No. ATCC 39989.

35

TABLE 11

Level of EPO Released into the Media				
	Sample	Assay	alpha medium harvest	0.02uM methotrexate in alpha medium harvest
40	Colony Pool A	RIA	3 ng/ml	42 ng/ml (pool) 150 ng/ml (clone)
		3H-Thy	--	1.5 U/ml
45	Single Colony clone (.02C-Z)	RIA	--	90 ng/ml
		3H-Thy	--	5.9 U/ml
	Microinjected pool (DEPO-1)	RIA	60 ng/ml	160 ng/ml
		3H-Thy	1.8 U/ml	--

50 [0073] The preferred single colony clone has been deposited and is available from the American Type Culture Collection, Rockville, Maryland under Accession Number ATCC CRL8695.

Example 12 : Expression of EPO Genomic Clone in COS-1 Cells

55 [0074] The vector used for expression of the EPO genomic clone is pSVOD (Mellon et al., *supra*). DNA from pSVOD was digested to completion with Hind III and blunted with the large fragment of DNA polymerase I. The EPO genomic clone lambda-HEPO3 was digested to completion with EcoRI and Hind III and the 4.0 kb fragment containing the EPO gene was isolated and blunted as above. The nucleotide sequence of this fragment from the Hind III site to a region

just beyond the polyadenylation signal is shown in Figure 4 and Table 4. The EPO gene fragment was inserted into the pSVOD plasmid fragment and correctly constructed recombinants in both orientations were isolated and verified. The plasmid CZ2-1 has the EPO gene in orientation "a" (i.e. with the 5' end of EPO nearest to the SV40 origin) and the plasmid CZ1-3 is in the opposite orientation (orientation "b").

5 [0075] The plasmids CZ1-3 and CZ2-1 were transfected into COS-1 cells as described in Example 7 and media was harvested and assayed for immunologically reactive EPO. Approximately 31 ng/ml of EPO was detected in the culture supernatant from CZ2-1 and 16-31 ng/ml from CZ1-3.

10 [0076] Genomic clones HEPO1, HEPO2, and HEPO6 can be inserted into COS cells for expression in a similar manner.

10

Example 13 : Expression In C127 and in 3T3 Cells Construction of pBPVEPO

15 [0077] A plasmid containing the EPO cDNA sequence under the transcriptional control of a mouse metallothionein promoter and linked to the complete bovine papilloma virus DNA was prepared as follows :

15

pEP049F

20 [0078] The plasmid SP6/5 was purchased from Promega Biotec. This plasmid was digested to completion with EcoRI and the 1340 bp EcoRI fragment from lambda-HEPOFL13 was inserted by DNA ligase. A resulting plasmid in which the 5' end of the EPO gene was nearest to the SP6 promoter (as determined by BglII and Hind III digestion) was termed pEPO49F. In this orientation, the BamHI site in the PSP6/5 polylinker is directly adjacent to the 5' end of the EPO gene.

pMMTneo BPV

25 [0079] The plasmid pdBPV-mmTneo (342-12) (Law et al., Mol. and Cell Biol. 3 : 2110-2115 (1983)), illustrated in Figure 8, was digested to completion with BamHI to produce two fragments - a large fragment ~8 kb in length containing the BPV genome and a smaller fragment, ~6.5 kb in length, containing the pML2 origin of replication and ampicillin resistance gene, the metallothionein promoter, the neomycin resistance gene, and the SV40 polyadenylation signal. The digested DNA was recircularized by DNA ligase and plasmids which contained only the 6.8 kb fragment were identified by EcoRI and BamHI restrictions endonuclease digestion. One such plasmid was termed pmmTneo BPV.

30

pEPO15a

35 [0080] pMMTneo BPV was digested to completion with BglII. pEP049f was digested to completion with BamHI and BglII and the approximately 700 bp fragment containing the entire EPO coding region was prepared by gel isolation. The BglII digested pMMTneo BPV and the 700 bp BamHI/BglII EPO fragment were ligated and resulting plasmids containing the EPO cDNA were identified by colony hybridization with an oligonucleotide d-(GGTCATCTGCCCC-GTCC) probe which is specific for the EPO gene. Of the plasmids which were positive by hybridization analysis, one (pEPO15a) which had the EPO cDNA in the orientation such that the 5' end of the EPO cDNA was nearest the metallothionein promoter was identified by digestion with EcoRI and KpnI.

40

pBPV-EPO

45 [0081] The plasmid pEPO15A was digested to completion with BamHI to linearize the plasmid. The plasmid pdBPV-MMT neo(342-12) was also digested to completion with BamHI to produce two fragments of 6.5 and 8 kb. The 8 kb fragment which contained the entire Bovine Papilloma Virus genome, was gel isolated. pEPO15a/BamHI and the 8kb BamHI fragment were ligated together and a plasmid (pBPV-EPO) which contained the BPV fragment were identified by colony hybridization using an oligonucleotide probe d(P-CCA-CACCCGGTACACA-OH) which is specific for the BPV genome. Digestion of pBPV-EPO DNA with Hind III indicated that the direction of transcription of the BPV genome was the same as the direction of transcription of the metallothionein promoter (as in pdBPV-MMTnec (342-12) see Figure 8). The plasmid pdBPV-MMTneo(342-12) is available from the American Type Culture Collection, Rockville, Maryland under Accession No. ATCC 37224.

50

Expression

55

[0082] The following methods were used to express EPO.

Method I.

5 [0083] DNA pBPV-EPO was prepared and approximately 25 ug was used to transfect $\sim 1 \times 10^6$ C127 (Lowy et al., *J. of Virol.* 26 : 291-98 (1978)) CHO cells using standard calcium phosphate precipitation techniques (Graham et al., *Virology*, 52 : 456-67 (1973)). Five hrs. after transfection, the transfection media was removed, the cells were glycerol shocked, washed, and fresh α -medium containing 10% fetal bovine serum was added. Forty-eight hrs. later, the cells were trypsinized and split at a ratio of 1 : 10 in DME medium containing 500 ug/ml G418 (Southern et al., *Mol. Appl. Genet.* 1: 327-41 (1982)) and the cells were incubated for two-three weeks. G418 resistant colonies were then isolated individually into microliter wells and grown until sub-confluent in the presence of G418. The cells were then washed, fresh media containing 10% fetal bovine serum was added and the media was harvested 24 hours later. The conditioned media was tested and shown to be positive for EPO by radioimmunoassay and by *in vitro* biological assay.

Method II

10 15 [0084] C127 or 3T3 cells were cotransfected with 25 ug of pBPV-EPO and 2 ug of pSV2neo (Southern et al., *supra*) as described in Method I. This is approximately at 10-fold molar excess of the pBPV-EPO. Following transfection, the procedure is the same as in Method I.

Method III

20 25 [0085] C127 cells were transfected with 30 ug of pBPV-EPO as described in Method I. Following transfection and splitting (1 : 10), fresh media was exchanged every three days. After approximately 2 weeks, foci of BPV transformed cells were apparent. Individual foci were picked separately into 1 cm wells of a microtiter plate, grown to a sub-confluent monolayer and assayed for EPO activity or antigenicity in the conditioned media.

Example 14 : Expression in Insect cells Construction of pIVEV EPOFL13

30 [0086] The plasmid vector pIVEV has been deposited and is available from the American Type Culture Collection, Rockville, Maryland under Accession No. ATCC 39991. The vector was modified as follows :

pIVEVNI

35 [0087] pIVEV was digested with EcoRI to linearize the plasmid, blunted using the large fragment of DNA polymerase I and a single NotI linker

40
 GGCGGCCGCC
 CCGCCGGCGG

was inserted by blunt end ligation. The resultant plasmid is termed pIVEVNI.

pIVEVSI


45 [0088] pIVEV was digested with SmaI to linearise the plasmid and a single SfiI linker

50
 GGGCCCCAGGGGGCCC
 CCCGGGGTCCCCGGG

was inserted by blunt end ligation. The resultant plasmid was termed pIVEVSI.

pIVEVSI BgKp

55 [0089] The plasmid pIVEVSI was digested with KpnI to linearize the plasmid and approximately 0 to 100 bp were removed from each end by digestion with the double-stranded exonuclease Bal 31. Any resulting ends which were not perfectly blunt were blunted using the large fragment of DNA polymerase I and the polylinker



was inserted by blunt end ligation. The polylinker was inserted in both orientations. A plasmid in which the polylinker is oriented such that the Bgll site within the polylinker is nearest to the polyhedron gene promoter is termed pIVEVSI-BgKp. A plasmid in which the Kpnl site within the polylinker is nearest to the polyhedron gene promoter is termed pIVEVSI-KpBg. The number of base pairs which were deleted between the original Kpnl site in pIVEVSI and the polyhedron promoter was not determined. The pIVEVSI-BgKp has been deposited with and is available from the American Type Culture Collection, Rockville, Maryland under Accession No. ATCC 39988.

15 pIVEVSI-BgKpN1

[0090] pIVEVNI was digested to completion with Kpnl and PstI to produce two fragments. The larger fragment, which contained the plasmid origin of replication and the 3' end of the polyhedron gene was prepared by gel isolation (fragment A). pIVEVSI-BgKp was digested to completion with PstI and KpnI to produce two fragments and the smaller fragment, which contained the polyhedron gene promoter and the polylinker was prepared by gel isolation (fragment B). Fragment A and B were then joined by DNA ligase to form the new plasmid pIVEV-SIBgKpN1 which contains a partially deleted polyhedron gene into which a polylinker has been inserted and also contains a NotI site (replacing the destroyed EcoRI site) and a SfiI site which flank the polyhedron gene region.

25 pIVEPO

[0091] pIVEVSI-BGKpNI was digested to completion with EcoRI to linearize the plasmid and the 1340 bp EcoRI fragment from lambda-HEPOFL13 was inserted. Plasmids containing the EPO gene in the orientation such that the 5' end of the EPO gene is nearest the polyhedron promoter and the 3' end of the polyhedron gene were identified by digestion with Bgll. One of these plasmids in the orientation described above was designated pIVEPO.

Expression of EPO In Insect Cells

[0092] Large amounts of the pIVEPO plasmid were made by transforming the E. coli strain JM101-tgl. The plasmid DNA was isolated by cleared lysate technique (Maniatis and Fritsch, Cold Spring Harbor Manual) and further purified by CsCl centrifugation. Wild-type Autographa californica polyhedrosis virus (AcNPV) strain L-1 DNA was prepared by phenol extraction of virus particles and subsequent CsCl purification of the viral DNA.

[0093] These two DNAs were then cotransfected into Spodoptera frugiperda cells IPLB-SF-21 (Vaughn et al., In Vitro Vol. B, pp. 213-17 (1977) using the Calcium phosphate transfection procedure (Potter and Miller, 1977). For each plate of cells being cotransfected, 1ug of wild-type AcNPV DNA and 10 ug of pIVEPO were used. The plates were incubated at 27°C for 5 days. The supernatant was then harvested and EPO expression in the supernatant was confirmed by radioimmunoassay and by in vitro biological assay.

45 Example 15 : Purification of EPO

[0094] COS-cell conditioned media (121) with EPO concentrations up to 200 ug/litre was concentrated to 600 ml using 10,000 molecular weight cutoff ultrafiltration membranes, such as a Millipore Pellican fitted with 5 sq. ft. of membrane. Assays were performed by RIA as described in Example 6. The retentate from the ultrafiltration was diafiltered against 4 ml. of 10 mM sodium phosphate buffered at pH 7.0. The concentrated and diafiltered condition media contained 2.5 mg of EPO in 380 mg of total protein. The EPO solution was further concentrated to 186 ml and the precipitated proteins were removed by centrifugation at 110,000 xg for 30 minutes.

[0095] The supernatant which contained EPO (2.0 mg) was adjusted to pH 5.5 with 50% acetic acid, allowed to stir at 4°C for 30 minutes and the precipitate removed by centrifugation at 13,000 xg for 30 minutes.

55 Carboxymethyl Sepharose Chromatography

[0096] The supernatant from the centrifugation (20 ml) containing 200 ug of EPO (24 mg total protein) was applied to a column packed with CM-Sepharose (20 ml) equilibrated in 10 mM sodium acetate pH 5.5, washed with 40 ml of

the same buffer. EPO which bound to the CM-Sepharose was eluted with a 100 ml gradient of NaU(0-1) in 10 mM sodium phosphate pH 5.5. The fractions containing EPO (total of 50 ug in 2 mg of total proteins) were pooled and concentrated to 2 ml using Amicon YM10 ultrafiltration membrane.

5 Reverse phase-HPLC

[0097] The concentrated fractions from CM-Sepharose containing the EPO was further purified by reverse phase-HPLC using Vydac C4 column. The EPO was applied onto the column equilibrated in 10% solvent B (Solvent A was 0.1% CF₃CO₂H in water; solvent B was 0.1% CF₃CO₂H in CF₃CN) at flow rate of 1 ml/min. The column was washed with 10% B for 10 minutes and the EPO was eluted with linear gradient of B (10-70% in 60 minutes). The fractions containing EPO were pooled (~40 ug of EPO in 120 ug of total proteins) and lyophilized. The lyophilized EPO was reconstituted in 0.1 M Tris-HCl at pH 7.5 containing 0.15 M NaCl and rechromatographed on the reverse phase HPLC. The fractions containing the EPO were pooled and analyzed by SDS-polyacrylamide (10%) gel electrophoresis (Lameli, U.K, Nature). The pooled fractions of EPO contained 15.5 ug of EPO in 25 ug of total protein.

10 [0098] The invention has been described in detail, including the preferred embodiments thereof. It will, however, be appreciated that those skilled artisans may make modifications and improvements upon consideration of the specification and drawings set forth herein, without departing from the spirit and scope of this invention as set forth in the appended claims.

20 REFERENCES

[0099]

- 1) Jacobson, L.O., Goldwasser, E. Fried, W., and Plzak, L.F., Trans. Assoc. Am. Physicians TO : 305-317 (1957).
- 25 2) Krantz, S.B. and Jacobson, L.O. Chicago : University of Chicago Press 1970, pp. 29-31.
- 3) Hammond, D and Winnick, S. Ann. N.Y. Acad. Sci. 230 : 219-227 (1974).
- 4) Sherwood, J.B. and Goldwasser, E., Endocrinology 103 : 866-870 (1978).
- 5) Fried, W. Blood 40: 671-677 (1972).
- 6) Fisher, J. J. Lab. and Clin. Med. 93 : 695-699 (1979).
- 7) Naughton, B.A., Kaplan, S.M., Roy, M., Burdowski, A.J., Gordon, A.S., and Piliero, S.J. Science 196: 301-302.
- 8) Lucarelli, G.P., Howard, D., and Stohlman, F., Jr. J. Clin. Invest 43 : 2195-2203 (1964).
- 9) Zanjani, E.D., Poster, J., Burlington, H., Mann, L.I., and Wasserman, L. R. J. Lab. Clin. Med. 89 : 640-644 (1977).
- 10) Krantz, S.B., Gallien-Lartigue, O., and Goldwasser, E. J. Biol. Chem. 238 : 4085-4090 (1963).
- 11) Dunn, C.D., Jarvis, J.H. and Greenman, J.M. Exp. Hematol. 3 : 65-78 (1975).
- 12) Krystal, G. Exp. Hematol. 11: 649-660 (1983)
- 13) Iscove, N.N. and Guilbert, L.J., M.J. Murphy, Jr. (Ed.) New York: Springer-Verlag, pp. 3-7 (1978).
- 14) Goldwasser, E., ICN UCLA Symposium, Control of Cellular Division and Development, A.R. Liss, Inc., pp. 487-494 (1981)
- 15) Cline, M.J. and Golde, D.W. Nature 277 : 177-181 (1979)
- 16) Metcalf, D., Johnson, G.R., and Burgess, A.W. Blood 55 : 138-(1980)
- 17) Krane, N. Henry Ford Hosp. Med. J. 31 : 177-181 (1983)
- 18) Eschbach, J., Madenovic, J., Garcia, J., Wahl, P., and Adamson, J.J. Clin. Invest. 74 ; 434-441 (1984)
- 19) Anagnostou, A., Barone, J., Vedo, A., and Fried, W. Br.J. Hematol 37 : 85-91 (1977)
- 20) Miyake, T., Kung, C., and Goldwasser, E.J. Biol. Chem. 252: 5558-5564 (1977)
- 21) Yanagawa, S., Hirade, K., Ohnita, H., Sasaki, R., Chiba, H., Veda, M., and Goto, M.J. Biol. Chem. 259 : 2707-2710 (1984)
- 22) Lawn, R.M., Fritsch, E.F., Parker, R.C., Blake, G., and Maniatis, T. Cell 15 : 1157-(1978)
- 23) Sanger, F., Nicklen, S., and Coulson, A.R. Proc. Nat'l. Acad. Sci., U.S.A. 74 : 5463— (1977)
- 24) Zanjanc, E.D., Ascensao, J.L., McGlave, P.B., Banisadre, M., and Ash, R.C. J. Clin. Invest. 67 : 1183-(1981)
- 25) Toole, J.J., Knopf, J.L., Wozney, J.M., Sultzman, L.A. Buecker, J. L., Pittman, D.D., Kaufman, R.J., Brown, E., Shoemaker, C., Orr, E.C., Amphlett, G.W., Foster, W.B., Coe, M.L., Knutson, G.J., Fass, D.N., and Hewick, R. M. Nature in Press
- 26) Goldwasser, E. Blood Suppl. 1, 58, xiii (abstr) (1981)
- 27) Sue, J.M. and Sylkowski, A.J. Proc. Natl Acad. Sci U.S.A. 80 : 3651-3655 (1983)
- 28) Bersch, N. and Golde, D.W., In Vitro Aspects of Erythropoiesis, M.J. Murphy (Ed.) New York : Springer-Verlag (1978)
- 29) Coles, P.M. and Bangham, D.R. Nature 191 : 1065-(1961)
- 30) Goldwasser, E. and Gross, M. Methods in Enzymol 37 : 109-121 (1975)

32) Nabeshima, Y. -i, Fujii-Kuriyama, Y., Muramatsu, M., and Ogata, K. Nature 308: 333-338 (1984)
 33) Young, RA, Hagencuhle, O. and Schibler, U. Cell 23 : 451-558 (1981)
 34) Medford, R.M., Nguyen, H.T., Destree, AT., Summers, E. and Nadal-Ginard, B. Cell 38 : 409-421 (1984)
 35) Ziff, E.B. Nature 287 : 491-499 (1980)
 5 36) Early, P. Cell 20 : 313-319 (1980)
 37) Sylkowski, A. Bio. Biop. Res. Comm. 96:143-149 (1980)
 38) Murphy, M. and Miyake, T. Acta. Haematol. Jpn. 46 : 1380-1396 (1983)
 39) Wagh, P.V. and Bahl, O.P. CRC Critical Reviews in Biochemistry 307-377 (1981)
 10 40) Wang, F.F., Kung, C.K. -H. and Goldwasser, E. Fed. Proc. Fed. Am. Soc. Exp. Biol. 42: 1872 (abstr) (1983)
 41) Lowy, P., Keighley, G. and Borsook, H. Nature 185 : 102-103 (1960)
 42) VanLenten, L. and Ashwell, G. J. Biol. Chem. 247 : 4633-4640 (1972)
 43) Lee-Huang. S. Proc. Natl Acad. Sci. U.S.A. 81 : 2708-2712 (1984)
 15 44) Fyhrquist, F., Rosenlof, K., Gronhagen-Riska, C., Horning, L. and Tikkannen, I. Nature 308: 649-562 (1984)
 45) Ohkubo, H., Kageyama, R., Vjihara, M., Hirose, T., Inayama, S., and Nakanishi, S. Proc. Nat'l Acad. Sci. U.S.
A. 80 : 2196-2200 (1983)
 46) Suggs, S.V., Wallace, R.B., Hirose, T., Kawashima, E.H. and Itakura, K. Proc. Nat'l. Acad. Sci. U.S.A. - 78 :
 6613-6617 (1981)
 47) Woo, S.L.C., Dugaiczyk, A., Tsai, M. -J., Lai, E.C., Catterall, J.F. and O'Malley, B.W. Proc Natl.-Acad. Sci. U.
S.A. 75 : 3588- (1978)
 20 48) Melchior, W.B. and VonHippel, P.H. Proc. Nat'l Acad. Soc. U.S.A. 70 : 298-302 (1973)
 49) Orosz, J.M. and Wetmisi, J.G. Biopolymers 16 ; 1183-1199 (1977)
 50) Anderson, S and Kingston, I.B. Proc. Nat'l Acad. Sci. - U.S.A. 80 : 6836-6842 (1983)
 51) Ullrich, A, Coussens, L., Hayflick, J.S. Dull, T.J., Gray, A., Tam, A.W., Lee, J., Yarden, Y., Libermann, TA.,
 Schlessinger, J., Downward. J.. Mayes. E.LV.. Whittle, H., Waterfield. M.D. and Seeburg, P.H. Nature 309 : 418-425
 25 (1984)
 52) Fisher, J. Proc. Soc. Exptl. Biol. and Med. 173 : 289-305 (1983)
 53) Kozak. M. Nuc. Acid Res. 12: 857-872 (1984)
 54) Benton, W.D. and Davis, R.W. Science 196: 180-182 (1977)
 55) Sherwood, J.B. and Goldwasser. E. Blood 54 : 885-893 (1979)
 30 56) Derman, E., Krauter, K., Walling, L., Weinberger, C., Ray, M., and Damell, J.T.. Cell 23 : 731- (1981)
 57) Gluzman, Y., Cell 23 : 175-182 (1981)
 58) Hewick, R.M., Hunkapiller, M.E., Hood, LE., and Dreyer, W.J. J. Biol. Chem. 256 : 7990-7997 (1981)
 59) Towbin, H., Stachelin, T., and Gordon, J.. Proc. Nat'l Acad. Sci. 76 : 4380- (1979)
 60) Carnott, P., Deflandre, C. C.R. Acad. Sci. Paris 143 : 432 - (1960).

35

Claims

40 Claims for the following Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Recombinant DNA plasmid vector containing cDNA encoding human EPO of clone lambda HEPOFL13 (ATCC 40153).

45 2. A mammalian cell transformed with the transfer vector of claim 1.

3. The cell of claim 2, wherein said mammalian cell is a 3T3, C127 or CHO cell.

50 4. A mammalian cell containing a plasmid which contains the entire bovine papilloma virus DNA and the cDNA sequence of Table 3 coding for human EPO.

5. The cell of claim 4, wherein said cell is a C127 or 3T3 cell.

6. The cell of claim 5, wherein said EPO DNA is under transcriptional control of a mouse metallothionein promoter.

55 7. The cell of claim 5, wherein said cell contains a plasmid comprising DNA from pdBPV-MMTneo (342-12) (ATCC 37224).

8. Method for producing recombinant human erythropoietin (hEPO) by the steps of

5 (a) culturing, in a suitable medium, CHO cells which contain, operatively linked to an expression control sequence, a DNA sequence encoding hEPO, and
(b) recovering and separating the recombinant hEPO produced from the cells and the medium,

characterized in that CHO cells are used which have the capability of producing N- and O-linked glycosylation, with incorporation of fucose and N-acetylgalactosamine, and that recombinant hEPO with N- and O-linked glycosylation is recovered and separated from the cells and the medium.

10 9. Method according to claim 8, wherein the recombinant hEPO has a glycosylation pattern comprising relative molar levels of hexoses to N-acetylglucosamine (Nacglc) of 1.4: 1, specifically galactose : Nacglc = 0.9 : 1 and mannose: Nacglc = 0.5: 1.

15 **Claims for the following Contracting State : AT**

20 1. A mammalian cell transformed with a transfer vector containing cDNA encoding human EPO of clone lambda HEPOFL13 (ATCC 40153).

25 2. The cell of claim 1, wherein said mammalian cell is a 3T3, C117 or CHO cell.

30 3. A mammalian cell containing a plasmid which contains the entire bovine papilloma virus DNA and the cDNA sequence of Table 3 coding for human EPO.

35 4. The cell of claim 3 wherein said cell is a C117 or 3T3 cell.

40 5. The cell of claim 4 wherein said EPO DNA is under transcriptional control of a mouse metallothionein promoter.

45 6. The cell of claim 4 wherein said cell contains a plasmid comprising DNA from pdBPV-MMT neo (342-12) (ATCC 37224)

7. Method for producing recombinant human erythropoietin (hEPO) by the steps of

50 (a) culturing, in a suitable medium, CHO cells which contain, operatively linked to an expression control sequence, a DNA sequence encoding hEPO, and
(b) recovering and separating the recombinant hEPO produced from the cells and the medium,

characterized in that CHO cells are used which have the capability of producing N- and O-linked glycosylation, with incorporation of fucose and N-acetylgalactosamine, and that recombinant hEPO with N- and O-linked glycosylation is recovered and separated from the cells and the medium.

40 8. Method according to claim 8, wherein the recombinant hEPO has a glycosylation pattern comprising relative molar levels of hexoses to N-acetylglucosamine (Nacglc) of 1.4: 1, specifically galactose : Nacglc = 0.9 : 1 and mannose: Nacglc = 0.5: 1.

Patentansprüche

50 **Patentansprüche für folgende Vertragsstaaten : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

55 1. Rekombinanter DNA Plasmidvektor, der für humanes EPO des Klons Lambda HEPOFL13 (ATCC 40153) kodierende cDNA enthält.

2. Säugerzelle, die mit dem Transfervektor nach Anspruch 1 transformiert ist.

3. Zelle nach Anspruch 2, worin die Säugerzelle eine 3T3-, C127-oder CHO-Zelle ist.

4. Säugerzelle, die ein Plasmid enthält, das die gesamte Rinder-Papillomavirus DNA und die für humanes EPO kodierende cDNA-Sequenz gemäß Tabelle 3 enthält.
5. Zelle nach Anspruch 4, worin die Zelle eine C127- oder 3T3-Zelle ist.
6. Zelle nach Anspruch 5, worin die EPO DNA unter transkriptionaler Kontrolle eines Maus-Metallothioneinpromotors ist.
7. Zelle nach Anspruch 5, worin die Zelle ein Plasmid enthält, das DNA aus pdBPV-MMTneo(342-12) (ATCC 37224) enthält.
8. Verfahren zur Herstellung von rekombinantem humanem Erythropoietin (hEPO) durch die Schritte:
 - (a) Kultivieren von CHO-Zellen, die eine für humanes Erythropoietin kodierende DNA-Sequenz enthalten, in einem geeigneten Medium, wobei die DNA-Sequenz operativ mit einer Expressionskontrollsequenz verknüpft ist, und
 - (b) Gewinnen und Abtrennen des rekombinanten hEPO von den Zellen und dem Medium,

dadurch gekennzeichnet, daß CHO-Zellen verwendet werden, welche die Fähigkeit zur Bildung von N- und O-verknüpfter Glykosylierung unter Einbau von Fucose und N-Acetylgalactosamin haben und daß rekombinantes hEPO mit N- und O-verknüpfter Glykosylierung gewonnen und von den Zellen und dem Medium abgetrennt wird.
9. Verfahren nach Anspruch 8, worin das rekombinante hEPO ein Glykosilierungsmuster hat, das relative molare Mengen von Hexosen zu N-Acetylglucosamin (NacGlc) von 1,4 : 1, insbesondere Galactose : NacGlc = 0,9 : 1 und Mannose : NacGlc = 0,5 : 1 umfaßt.

Patentansprüche für folgenden Vertragsstaat : AT

1. Säugerzelle, die mit einem Transfervektor transformiert ist, der für humanes EPO des Klons Lambda HEPOFL13 (ATCC 40153) kodierende cDNA enthält.
2. Zelle nach Anspruch 1, worin die Säugerzelle eine 3T3-, C127- oder CHO-Zelle ist.
3. Säugerzelle, die ein Plasmid enthält, das die gesamte Rinder-Papillomavirus DNA und die für humanes EPO kodierende cDNA-Sequenz gemäß Tabelle 3 enthält.
4. Zelle nach Anspruch 3, worin die Zelle eine C127- oder 3T3-Zelle ist.
5. Zelle nach Anspruch 4, worin die EPO DNA unter transkriptionaler Kontrolle eines Maus-Metallothioneinpromotors ist.
6. Zelle nach Anspruch 4, worin die Zelle ein Plasmid enthält, das DNA aus pdBPV-MMTneo(342-12) (ATCC 37224) enthält.
7. Verfahren zur Herstellung von rekombinantem humanem Erythropoietin (hEPO) durch die Schritte:
 - (a) Kultivieren von CHO-Zellen, die eine für humanes Erythropoietin kodierende DNA-Sequenz enthalten, in einem geeigneten Medium, wobei die DNA-Sequenz operativ mit einer Expressionskontrollsequenz verknüpft ist, und
 - (b) Gewinnen und Abtrennen des gebildeten rekombinanten hEPO von den Zellen und dem Medium,

dadurch gekennzeichnet, daß CHO-Zellen verwendet werden, welche die Fähigkeit zur Bildung von N- und O-verknüpfter Glykosylierung unter Einbau von Fucose und N-Acetylgalactosamin haben und daß rekombinantes hEPO mit N- und O-verknüpfter Glykosylierung gewonnen und von den Zellen und dem Medium abgetrennt wird.
8. Verfahren nach Anspruch 7, worin das rekombinante hEPO ein Glykosilierungsmuster hat, das relative molare Mengen von Hexosen zu N-Acetylglucosamin (NacGlc) von 1,4 : 1, insbesondere Galactose : NacGlc = 0,9 : 1 und

Mannose : Nacglc = 0,5 : 1 umfaßt.

Revendications

5

Revendications pour les Etats contractants suivants : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

10 1. Vecteur plasmidique d'ADN recombiné contenant un ADNc codant l'EPO humaine du clone lambda HEPOFL13 (ATCC 40153).

2. Cellule de mammifère transformée avec le vecteur de transfert selon la revendication 1.

15 3. Cellule selon la revendication 2, dans laquelle ladite cellule de mammifère est une cellule 3T3, C127 ou CHO.

4. Cellule de mammifère contenant un plasmide qui contient l'ADN complet du virus du papillome bovin et la séquence d'ADNc du tableau 3 codant l'EPO humaine.

20 5. Cellule selon la revendication 4, dans laquelle ladite cellule est une cellule C127 ou 3T3.

6. Cellule selon la revendication 5, dans laquelle ledit ADN d'EPO est sous le contrôle transcriptionnel d'un promoteur de métallothionéine de souris.

25 7. Cellule selon la revendication 5, dans laquelle ladite cellule contient un plasmide comprenant un ADN issu de pdBPV-MMTneo(342-12) (ATCC 37224).

8. Procédé de production d'érythropoïétine humaine (hEPO) recombinée par les étapes consistant à :

30 a) cultiver dans un milieu approprié des cellules CHO qui contiennent une séquence d'ADN codant la hEPO, liée de façon active à une séquence de contrôle de l'expression, et

b) récupérer et séparer la hEPO recombinée produite à partir des cellules et du milieu,

35 caractérisé en ce que l'on utilise des cellules CHO qui sont capables de produire une glycosylation N- et O-liée, avec incorporation de fucose et de N-acétylgalactosamine, et en ce qu'une hEPO recombinée à glycosylation N- et O-liée est récupérée et séparée à partir des cellules et du milieu.

40 9. Procédé selon la revendication 8, dans lequel la hEPO recombinée a un motif de glycosylation comprenant des niveaux molaires relatifs d'hexoses à la N-acétylglicosamine (Nacglc) de 1,4 : 1, spécifiquement de galactose: Nacglc = 0,9 : 1 et de mannose:Nacglc = 0,5 : 1.

Revendications pour l'Etat contractant suivant : AT

45 1. Cellule de mammifère transformée avec vecteur de transfert contenant un ADNc codant l'EPO humaine du clone lambda HEPOFL13 (ATCC 40153).

2. Cellule selon la revendication 1, dans laquelle ladite cellule de mammifère est une cellule 3T3, C127 ou CHO.

50 3. Cellule de mammifère contenant un plasmide qui contient l'ADN complet du virus du papillome bovin et la séquence d'ADNc du tableau 3 codant l'EPO humaine.

4. Cellule selon la revendication 3, dans laquelle ladite cellule est une cellule C127 ou 3T3.

55 5. Cellule selon la revendication 4, dans laquelle ledit ADN d'EPO est sous le contrôle transcriptionnel d'un promoteur de métallothionéine de souris.

6. Cellule selon la revendication 4, dans laquelle ladite cellule contient un plasmide comprenant un ADN issu de pdBPV-MMTneo(342-12) (ATCC 37224).

7. Procédé de production d'érythropoïétine humaine (hEPO) recombinée par les étapes consistant à

5 a) cultiver dans un milieu approprié des cellules CHO qui contiennent une séquence d'ADN codant la hEPO, liée de façon active à une séquence de contrôle de l'expression, et
b) récupérer et séparer la hEPO recombinée produite à partir des cellules et du milieu,

10 caractérisé en ce que l'on utilise des cellules CHO qui sont capables de produire une glycosylation N- et O-liée, avec incorporation de fucose et de N-acétylgalactosamine, et en ce qu'une hEPO recombinée à glycosylation N- et O-liée est récupérée et séparée à partir des cellules et du milieu.

15 8. Procédé selon la revendication 7, dans lequel la hEPO recombinée a un motif de glycosylation comprenant des niveaux molaires relatifs d'hexoses à la N-acétylglicosamine (NacGlc) de 1,4 : 1, spécifiquement de galactose: NacGlc = 0,9 : 1 et de mannose:NacGlc = 0,5 : 1.

15

20

25

30

35

40

45

50

55




FIG. 1




FIG. 2

FIG. 3





FIG. 4






FIG. 5A





FIG. 5B







FIG. 5C






FIG. 6

FIG. 7




FIG. 8

